Version 0 3/22/2022  page 1 of 63  
 
 
A Phase  II Randomized,  Double -Blind , Placebo -Controlled  Trial  to Evaluate  Uproleselan  
(GMI -1271)  for GI Toxicity  Prophylaxis  During  Melphalan- Conditioned Autologous  
Hematopoietic  Cell  Transplantation  (auto -HCT)  for Multiple  Myeloma  (MM)  
 
Washington University School of Medicine  
Division of Oncology 
660 South E uclid Avenue, Campus Box 8007 
St. Louis, MO  63110 
 
 
Protocol  #: 202103086 
Version Date: 22 March 2022 
  
Principal Investigator:  Keith Stockerl -Goldstein , M.D. 
Phone:  (314) 454- 8304  
E-mail:  ksgoldstein@wustl.edu
  
 
Sub- Investigators    Modality  
Zachary D. Crees, M.D.  Bone Marrow Transplant  
Geoffrey Uy , M.D.    Bone Marrow Transplant  
Phillip Tarr, M.D.    Gastroenterology 
Feng Gao, M.D., Ph.D.   Biostatistics  
   
 
Study Drug(s):   Uproles elan (GM -1271)  
IND#:  154990 
IND Sponsor:  Keith Stockerl- Goldstein, M.D. 
NCT#:  [STUDY_ID_REMOVED] 
Funded by:  Glyco Mimetics, Inc.  (drug only)  
 Foundation for Barnes -Jewish Hospital  
 
 
 
 
 
CONFIDENTIAL  
The information contained in this document is regarded as confidential and, except to the extent necessary to 
obtain informed consent, may not be disclosed to another party unless law or regulations require such 
disclosure.  Persons to whom the information is disclosed must be informed that the information is 
confidential and may not be further disclosed by them . 
 
  

Version 0 3/22/2022  page 2 of 63 A Phase  II Randomized,  Double -Blind , Placebo -Controlled  Trial  to Evaluate  Uproleselan  
(GMI -1271)  for GI Toxicity  Prophylaxis  During  Melphalan- Conditioned Autologous  
Hematopoietic  Cell  Transplantation  (auto -HCT)  for Multiple  Myeloma  (MM)  
 
Protocol Revision History  
 
Initial Approval Version        01 March 2021 
Amendment #1 Version        01 June 2021 
Amendment #2 Version        22 March 2022 
 
  
Version 0 3/22/2022  page 3 of 63 STATEMENT OF COMPLIANCE 
The trial will be carried out in accordance with International Conference on Harmonisation Good 
Clinical Practice (ICH GCP) and the following:  
 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)  
 National Institutes of Health (NIH)- funded investigators and clinical trial site sta ff who are 
responsible for the conduct, management, or oversight of NIH -funded clinical trials  have 
completed Human Subjects Protection and ICH GCP Training. 
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will  
be submitted to the Institutional Review Board (IRB) for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled.  Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study.  In addition, all changes to the consent form will be IRB -approved; a 
determination will be made regarding whether a new consent needs to be obtained from participants who provided consent, using a previously approved consent form . 
  
 
 
  
  
Version 0 3/22/2022  page 4 of 63 Glossary of Abbreviations  
 
AE Adverse event  
ALT (SGPT)  Alanine transaminase (serum glutamate pyruvic transaminase)  
AML  Acute myeloid leukemia  
ANC  Absolute neutrophil count  
AST (SGOT)  Aspartate transaminase (serum glutamic oxaloacetic transaminase)  
B-HCG  Beta human chorionic gonadotropin  
BMT  Bone marrow transplant  
CBC Complete blood count  
CFR Code of Federal Regulations  
CNS  Central nervous system  
CR Complete re sponse  
CRc Cytogenetic complete remission  
CRi Complete remission incomplete  
CRm  Morphologic complete remission  
CRF  Case report form  
CST Central standard time  
CT Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTEP  Cancer Therapy Evaluation Program  
DLT  Dose limiting toxicity  
DNA  deoxyribonucleic acid  
DSM  Data and Safety Monitoring  
DSMC  Data Safety Monitoring Committee  
ECG (or EKG)  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group 
EDTA  ethylenediaminetetraacetic acid  
FDA Food and Drug Administration 
FISH  fluorescent in situ hybridization  
FWA  Federal wide assurance  
GCP  Good Clinical Practice  
HHS  Departme nt of Health and Human Services  
HIV Human Immunodeficiency Virus  
HRPO  Human Research Protection Office (IRB)  
IND Investigational New Drug  
IRB Institutional Review Board  
MDS  Myelodysplastic syndrome  
MM Multiple myeloma  
MRI  Magnetic resonance imaging  
MTD Maximum tolerated dose  
NCCN  National Cancer Center Network  
Version 0 3/22/2022  page 5 of 63 NCI National Cancer Institute  
NIH National Institutes of Health  
OHRP  Office of Human Research Protections  
ORR Overall response rate  
OS Overall survival  
PBMC  Peripheral blood mononuclear cell  
PD Progressive disease 
PI Principal investigator  
PR Partial response  
QASMC  Quality Assurance and Safety Monitoring Committee  
RFS Relapse free survival  
RR Response rate  
SAE  Serious adverse event  
SCC Siteman Cancer Center  
SCT Stem cell transplant  
SD Stable disease  
TSH  Thyroid stimulating hormone  
TTP Time to progression  
UPN  Unique patient number  
US Ultrasound 
WBC White blood cell (count)  
  
  
  
  
 
                 
Version 0 3/22/2022  page 6 of 63 Table of Contents  
PROTOCOL SUMMARY  .............................................................................................................. 8 
SCHEMA  ...................................................................................................................................... 11 
SCHEDULE OF ACTIVITIES  ..................................................................................................... 12 
1.0 INTRODUCTION  ............................................................................................................. 13 
1.1 Background .................................................................................................................... 13 
1.2 Study Design .................................................................................................................. 17 
1.3 Risk/Benefit Assessment  ................................................................................................ 18 
2.0 OBJECTIVES AND ENDPOINTS  ................................................................................... 20 
3.0 STUDY POPULATION  .................................................................................................... 21 
3.1 Inclusion Criteria  ............................................................................................................ 21 
3.2 Exclusion Criteria  ........................................................................................................... 22 
3.3 Inclusion of Women and Minorities  ............................................................................... 24 
4.0 REGISTRATION PROCEDURES  ................................................................................... 24 
4.1 Confirmation of Patient Eligibility  ................................................................................. 24 
4.2 Patient Registration in the Siteman Cancer Center OnCore Database  ........................... 24 
4.3 Assignment of UPN  ....................................................................................................... 24 
4.4 Screen F ailures  ............................................................................................................... 24 
4.5 Measures to Minimize Bias:  Randomization and Blinding  .......................................... 25 
4.6 Replacement of Patients  ................................................................................................. 26 
5.0 TREATMENT PLAN  ........................................................................................................ 26 
5.1 Study Intervention Description  ...................................................................................... 26 
5.2 Definitions of Evaluability  ............................................................................................. 28 
5.3 Concomitant Therapy and Supportive Care Guidelines  ................................................. 29 
5.4 Women of Childbearing Potential  .................................................................................. 29 
5.5 Duration of Therapy  ....................................................................................................... 30 
5.6 Duration of Follow -up .................................................................................................... 30 
5.7 Lost to Follow -Up .......................................................................................................... 31 
6.0 DOSE DELAYS/DOSE MODIFICATIONS  .................................................................... 31 
7.0 REGULATORY AND REPORTING REQUIREMENTS  ............................................... 31 
7.1 Sponsor -Investigator Reporting Requirements  .............................................................. 32 
7.2 Exceptions to Expedited Reporting  ................................................................................ 34 
8.0 PHARMACEUTICAL INFORMATION .......................................................................... 34 
8.1 Uproleselan (GMI -1271)  ................................................................................................ 34 
8.2 Placebo  ........................................................................................................................... 36 
9.0 CORRELATIVE STUDIES .............................................................................................. 37 
9.1 Minimal Residual Disease (MRD) Status Following HCT  ............................................ 37 
9.2 E-selectin Levels  ............................................................................................................ 38 
9.3 GI Epithelial Inflammation and Permeability Biomarkers  ............................................ 39 
10.0 DATA SUBMISSION SCHEDULE  ................................................................................. 39 
10.1 Adverse Event Collection in the Case Report Forms  ..................................................... 40 
11.0 MEASUREMENT OF EFFECT ........................................................................................ 40 
11.1 GI Toxicity Adverse Events  ........................................................................................... 40 
11.2 Response Criteria  ........................................................................................................... 42 
11.3 Progression- Free Survival  .............................................................................................. 45 
11.4 Overall Survival  ............................................................................................................. 46 
Version 0 3/22/2022  page 7 of 63 11.5 Overall Response Rate  ................................................................................................... 46 
11.6 Complete Response Rate ................................................................................................ 46 
12.0 DATA AND SAFETY MONITORING  ............................................................................ 46 
13.0 STATISTICAL CONSIDERATIONS............................................................................... 47 
13.1 Statistical Hypotheses  .................................................................................................... 47 
13.2 Sample Size Determination  ............................................................................................ 47 
13.3 Population for Analyses  ................................................................................................. 48 
13.4 Statistical Analyses  ........................................................................................................ 48 
14.0 REFERENCES .................................................................................................................. 52 
APPENDIX A: ECOG P erformance Status Scale  ........................................................................ 55 
APPENDIX B: Definitions for Adverse Event Reporting  ............................................................ 56 
APPENDIX C: Reporting Timelines  ............................................................................................ 58 
APPENDIX D: Bristol Stool Scale  ............................................................................................... 61 
SUPPLEMENT 1: GI -Specific NCI CTCAE PRO v1.0  .............................................................. 62 
  
Version 0 3/22/2022  page 8 of 63 PROTOCOL SUMMARY  
 
Title:  A Phase  II Randomized,  Double -Blind , Placebo -Controlled  Trial  to 
Evaluate  Uproleselan  (GMI -1271)  for GI Toxicity Prophylaxis  
During Melphalan -Conditioned Autologous  Hematopoietic  Cell 
Transplantation  (auto -HCT)  for Multiple  Myeloma  (MM)  
Study Description:  This is a Phase II, single -center, randomized, double -blind, placebo -
controlled clinical trial. Eligible patients undergoing first auto-HCT 
with melphalan conditioning (200mg/m2) for MM will be 
randomized in a 1:1 allocation to receive either prophylactic 
uproleselan + SOC or placebo + SOC.  Randomization wil l be 
stratified by age ≥65 years and <65 years, due to increased frequency 
of GI toxicity in elderly populations.  
Objectives:  Primary Outcome:  
To demonstrate the superiority of prophylactic uproleselan (GMI-
1271) plus standard of care (SOC) compared to placebo plus SOC to 
reduce diarrhea severity in patients receiving high -dose melphalan 
conditioning in preparation for auto- HCT in MM.  
 
Secondary Outcomes:  
• To demonstrate the superiority of prophylactic uproleselan 
(GMI -1271) plus SOC compared to placebo plus SOC to:  
o Reduce oral mucositis severity  
o Reduce alternative GI toxicities (e.g.  esophagitis, 
enterocolitis , etc. ) 
• To descriptively assess the effects of prophylactic uproleselan 
(GMI -1271) plus SOC compared to placebo plus SOC on:  
o Time to engraftment  
o hospital length of stay (LOS) 
o Use of anti -diarrheal and pain medications  
o Patient nutritional status pre-conditioning and post -HCT  
o Change in Bristol Stool Scale  
o Incidence of post -HCT infection prior to engraftment  
• To descriptively assess the effects of prophy lactic uproleselan 
(GMI -1271) plus SOC compared to placebo plus SOC on PRO 
and QoL related to GI toxicity, on D-3, D+8 and date of discharge 
or D+14 (whichever is sooner)  
 
Exploratory Outcomes:  
• To descriptively assess the effects of prophylactic uproleselan 
(GMI -1271) plus SOC compared to placebo plus SOC on:  
o Minimal Residual Disease (MRD) at 100 days post -HCT  
o Soluble E -selectin levels at pre -dose (D -3) and post -
conditioning (D -0) time points  
o Progression Free Survival (PFS)  
o Overall Survival (OS)  
Version 0 3/22/2022  page 9 of 63 • To descriptively assess biomarkers of GI permeability  and GI 
epithelial injury , in collaboration with the Division of 
Gastroenterology  
Endpoints:  Primary Endpoint:  
Change  in diarrhea severity , assessed per CTCAE v5.0, in patients 
receiving high- dose melphalan conditioning in preparation for auto -
HCT for MM  who receive prophylactic uproleselan (GMI -1271) 
plus standard of care (SOC) compared to placebo plus SOC.  
 
Secondary Endpoint s: 
• Change in mucositis severity , per CT CAE v5.0 Oral Mucositis 
criteria  
• Change in alternative GI toxicities (e.g. esophagitis , 
enterocolitis , etc; per CTCAE v5.0)  
• Time to neutrophil engraftment defined as ANC ≥0.5 x 109/L for 
3 consecutive days or ≥1.0 x 109/L for 1 day  
• Duration of hospital length of stay (LOS), from date of admission 
for auto- HCT to date of discharge  
• Quantitative use of anti- diarrheal medications (loperamide, 
diphenoxylate, etc.)  and pain medications (e.g. opioids converted 
to morphine equivalents)  
• Patient nutritional status  before conditioning and at D+14 or date 
of discharge (whichever is sooner), as assessed by total TPN days and change in standing weight comparing D -3, D+8 and date of 
discharge or D+14 (whichever is sooner)  
• Change in Bristol Stool Scale , assessed daily  
• Incidence of infection assessed by rates of bacteremia (with 
organism reported when available) , time to first antibiotics  and 
c. diff  infections  
• PRO and QoL, per the CTCAE PRO Form v1.0 with items selected 
for relevance to GI toxicity and patient QoL (see Supplement 1), 
assessed on D-3, D+8 and date of discharge  or D+14 (whichever 
is sooner)  
 
Exploratory  Endpoints:  
• Post-HCT Minimal Residual Disease (MRD) testing at D+100 
via ImmunoSeq B -cell receptor sequencing (Adaptive 
Biotechnologies)  
• Soluble E -selec tin levels by ELISA assay at pre- dose (D -3) and 
post-conditioning (D -0) time points  
• Progression Free Survival (PFS) with up to 2-year follow up 
assessed by time- to event (Kaplan -Meier analysis)  
• Overall Survival (OS) with up to 2 -year follow up assessed by 
time-to event (Kaplan -Meier analysis)  
Version 0 3/22/2022  page 10 of 63 • Fecal calprotectin and neutrophil gelatinase -associated lipocalin -
2 (lipocalin -2) biomarkers  (Tarr Lab) on D-3, D0, D+8 and date 
of discharge  or D+14 (whichever is sooner)  
Study Population:  Fifty p atients with biopsy -proven diagnosis of multiple myeloma 
(MM) aged 18 -75 years are eligible for this study. Must have ECOG 
PS 0 -1, undergoing first  auto- HCT for MM in first PR or better. 
Patients requiring renal replace ment  therapy, with a history of 
inflammatory bowel disease or alternative chronic diarrheal 
syndrome will be excluded.  
Phase:  Phase II  
Description of Study 
Intervention:  Patients enrolled on study will receive investigational 
product /placebo for 3 consecuti ve days totaling 6 doses. Follow -up 
for the key secondary endpoints of engraftment will include D+30, 
D+100, 6- month and 12- month assessments. The remaining follow -
up will be conducted via phone -calls every 3- 6 months to assess for 
PFS and OS for up to 2 years post -HCT.  
Study Duration:  12 months (recruitment) + 24 months (intervention and follow -up) + 
12 months (data analysis) = 48 months.  
Participant Duration:  Approximately 1 week  of active study intervention  (participants will 
be in- patient during this period); 1 year of in -person follow -up; 1 
year of  phone and medical record follow -up.  
   
  
  
  
Version 0 3/22/2022  page 11 of 63 SCHEMA  
 
 
 
 
  

Version 0 3/22/2022  page 12 of 63 SCHEDULE OF ACTIVITIES  
 
Activity  
Screening1 
Day -3 
Day -2 
Day -1 
Day 0  
Day +1  
Day + 8 
DOD  or D + 1412 
Follow -Up13 
Informed consent  X         
Eligibility check  X         
Physical exam  X        X 
Medical history  X         
Laboratory evaluation  X2 daily labs as per BMT protocol  X 
Pregnancy test3 X X        
Randomization4 X         
Bone marrow evaluation  X5        X5 
Soluble E -selectin levels  (peripheral blood)   X   X     
Fecal calprotectin and lipocalin -2 biomarkers   X   X  X X  
Uproleselan 800 mg (iv) or placebo (iv) q 12 hrs   X X6 X X     
Melphalan conditioning 200 mg/m2   X6       
HSC infusion      X7     
Standing weight (unless unable to stand)  X X     X X  
NCI PRO CTCAE QoL assessment8  X     X X  
Standard AE assessments9 X X------------------ daily ------------------ X X 
Study -specific CTCAE v5.0 AE assessments10 X X------------------ daily ------------------ X  
Bristol Stool Scale assessment11  X------------------ daily ------------------ X  
1. Screening window to be D- 90 through D -3 
2. CBC with differential, CMP, PT/INR, PTT, HIV and acute hepatitis panel . 
3. For women of childbearing potential, pregnancy test must be obtained at screening and on admission to the hospital prior to 
starting treatment on study . 
4. Randomization will occur following consent, screening and confirmation of eligibility . 
5. Screening and D+100 bone marrow assessment to include MRD testing  of bone marrow aspirate  on all patients . Otherwise, bone 
marrow assessments  to be  conducted per standard of care  and institutional practice  for disease response assessments.  
6. 3 doses of uproleselan should be  administered prior to administration of the melphalan conditioning regimen  and 3 doses of 
uproleselan administered following administration of the melphalan conditioning regimen.  
7. HSC infusion 4 hours (+/-  2 hours) following last dose of uproleselan . 
8. See Supplement 1  for CTI PRO  CTCAE  assessment form . 
9. Baseline AE assessment is intended to establish patient’s current medical condition. No regulatory reporting of AEs at baseline 
is required  unless occurring as a result of a study -related procedure.   AEs are collected through D+30.  
10. Baseline and D -3 through DOD study -specific AE assessments must include the study specific CTCAE v5.0 assessments for the 
primary and secondary endpoints (see Section 11.0).  
11. See Appendix D . 
12. DOD = date of discharge . Assessment on DOD  or D+ 14, whichever is s ooner .  
13. Follow -up assessments will take place after transplant, at D+30, D+100, 6 months, and 12 months. Medical record data will be 
collected for up to 2 years post- HCT  for survival . 
 
 
 
Version 0 3/22/2022  page 13 of 63 1.0 INTRODUCTION  
 
1.1 Background  
 
1.1.1 Multiple Myeloma  
 
Multiple myeloma (MM) is a malignancy of plasma cells resulting in infiltration of the bone marrow, pancytopenia and lytic bone lesions.  MM is the second most common hematologic malignancy
1-3 and accounts for approximately 15% of all 
hematologic malignanc ies4. The median age of patien ts at the time of diagnosis is 
approximately 65 years  and impacts African Americans at rates 2 -3x higher than 
rest of the population5. Common clinical features of MM are bone pain with 
pathologic fractures secondary to lytic lesions, renal failure, fatigue secondary to anemia and recurrent infections
5. 
 
1.1.2 High -dose Chemotherapy and Stem -cell Rescue Therapy  
 
Historically, with conventional chemotherapy, median overall survival for MM 
patients was 24 -30 months. In the 1980s, high- dose chemotherapy and stem -cell 
rescue therapy via autologous hematopoietic cell transplantation (auto -HCT) was 
introduced. In subsequent randomized trials, auto- HCT for the treatment of MM 
has been shown to improve event free survival compared to conventi onal 
chemotherapy alone in patients with standard -risk MM, while lengthening the time 
patients are without symptoms, treatment and treatment toxicity6-8. Currently, a 
combined approach of auto- HCT with additional novel therapies has increased 
median overal l survival to >80 months9-13. 
 
1.1.3 Chemotherapy -Related GI Toxicity  
 
The conditioning regimens used for preparative chemotherapy prior to rescue auto -
HCT are associated with high rates (70-80%)  of both hematologic and non-
hematologic AEs14-15. High- dose melphalan, which is one of the most commonly 
used regimens, carries particularly high rates of GI toxicity  with diarrhea  occurring 
in >90% of patients15-16. These toxicities adversely affect patients and frequently 
increase healthcare utilization by increa sing hospital length of stay (LOS), 
increasing palliative medication usage, decreasing nutritional status, worsening 
patient quality of life (QoL) and having a detrimental impact on clinical outcomes17-
20. Meanwhile, current management strategies focus pri marily on palliation of the 
GI toxicity once it has occurred, rather than preventing its occurrence21. Improved, 
prophylactic strategies are needed.  
 
1.1.4 Gastrointestinal Inflammation and Permeability  
 
Although t he underlying mechanism of chemotherapy -related GI toxicity is not 
completely understood, i t is well -documented that cytotoxic chemotherapy 
disproportionately impacts cell populations with high turnover, including 
Version 0 3/22/2022  page 14 of 63 malignant cells as well as highly proliferative normal tissues like the GI epithelium, 
likely contributing to high rates of GI toxicity (diarrhea, mucositis, etc.). However, a growing body of dat a suggest that this chemotherapy -initiated epithelial injury 
subsequently leads to inflammatory chemokine and cytokine signaling, as well as  
upregul ated selectin and integrin expression on the vascular endothelium at sites of 
inflammation
22, 23. For example, upregulated E -selectin expression has been shown 
to be as high as 10 x the baseline levels on vascular endothelial cells at sites GI 
epithelial in flammation23. This leads to increased intravascular leukocyte rolling, 
adhesion, trans -endothelial migration and chemotaxis of proinflammatory cells to 
these sites of epithelial injury resulting in additional , pathologic  immune -mediated 
inflammatory injury  to the GI epithelium22,23.  
 This concept of pathologic, inflammatory GI epithelial injury by inflammatory leukocytes has been well -described in alternative settings of GI injury, such as graft 
versus host disease (GHVD)  and inflammatory bowel disease (IBD)
24-26. Therefore, 
in addition to evaluating mechanisms of inflammat ion as a therapeutic target for 
intervention in inflammatory GI disorders, the development of diagnostic 
biomarkers of GI inflammation represents an active area of investigation. Some 
well-described inflammatory markers of intestinal inflammation in  GVHD and IBD 
include fecal calprotectin24-26, fecal lipocalin -227, 28 and fecal neopterin29, 30, which 
have been shown to correlate with severity of GI inflammatory epithelial injury and 
have been investigated as measures of treatment response leading to decreased GI 
inflammation .  
 
Therefore, presence of increased biomarkers of GI inflammation would represent 
strong supportive evidence of the proposed mechanism of chemotherapy- initiated 
epithe lial injury leading to further inflammatory -mediated GI toxicity.  
 
1.1.5 E-Selectin  
 
E-selectin is a highly conserved adhesion molecule expressed on the surface of 
vascular endothelial cells which is upregulated at sites of inflammation, leading to increased in travascular cell rolling, trans -endothelial migration and trafficking of 
proinflammatory cells to these sites of inflammation
22. Emerging pre -clinical data 
suggest that c hemotherapy- induced mucositis and neutropenia may also be 
associated with E -selectin u p-regulation on vascular endothelium at sites of acute 
chemotherapy- related inflammation along the GI epithelium, leading to additional 
cell-mediated inflammatory epithelial injury23. E-selectin is also constitutively 
expressed in vascular niches within th e bone marrow, where it has been shown to 
co-localize and bind with malignant acute myeloid leukemia (AML) and multiple 
myeloma (MM) cells leading to cell adhesion -mediated chemotherapy resistance31-
33. 
 
1.1.6 Investigational Intervention  – Uproleselan (GMI- 1271)  
 
Uproleselan is a synthetic E -selectin antagonist which competitively inhibits E -
Version 0 3/22/2022  page 15 of 63 selectin, thereby interrupting E -selectin -mediated interactions and effects34. 
 
1.1.6.1 Pre-Clinical Data  
 
Pre-clinical trials suggest that chemotherapy- induced mucositis and 
neutropenia may be associated with E -selectin up -regulation, while E -
selectin inhibition with uproleselan as an adjunct to chemotherapy protected 
mice from weight loss and chemotherapy induced GI toxicity while also enhancing neutrophil recovery
23. Importantly, the administration of 
uproleselan effectively blocked secondary migration of inflammatory F4/80+ Ly- 6C+ macrophages to intestines of mice following chemotherapy 
as one mechanism of reduced GI toxicity  (Figure 1)
23, 34.  
 
Figure 1: Macrophage Staining of Murine Small Intestines after Administration of Chemotherapy 
Alone and in Combination with Uproleselan (GMI -1271)  
 
A. Chemotherapy- treated with saline control injections, sustained epithelial injury, substantial 
macrophage infiltration, villous loss and epithelial erosions. B. Chemotherapy- treated, 
uproleselan -injected (GMI- 1271), prevented macrophage infiltration, villous loss and epithelial 
injury.  
 
E-selectin inhibition with uproleselan in various pre -clinical models has 
also been observed to disrupt adhesion and mobilize malignant cells into circulation, increasing sensitivity to cytotoxic chemotherapy
31, 35 
Interesti ngly, treatment with uproleselan resulted in mobilization of MM 
cells to the peripheral blood beyond drug elimination in mouse xenograft 
models, suggesting a sustained effect following drug administration35. 
Additional in vivo studies using MM mouse models  evaluating uproleselan 
plus melphalan demonstrated significantly improved survival and tumor 
growth inhibition when compared to melphalan alone35.   
 
1.1.6.1 Clinical Data  
 
To date, E -selectin inhibition with uproleselan has been evaluated in a total 
of 6 early -phase clinical trials conducted in healthy volunteers 
([STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED]), AML ([STUDY_ID_REMOVED]) 
- A 
 - B 
Version 0 3/22/2022  page 16 of 63 and MM with an acceptable safety, pharmacokinetic (PK), 
pharmacodynamic (PD) profile34. In a recently completed Phase I/II clinical 
trial ([STUDY_ID_REMOVED]) evaluating uproleselan plus chemotherapy in patients with AML demonstrated promising overall response rates of 80% (newly Dx AML, 7+3 chemo) and 48% (relapsed/refractory, MEC chemo), leading to a Phase III trial ([STUDY_ID_REMOVED]) which our group is currently participating in
34. Interestingly, only 4/157 (2.5%) of AML patients treated 
with uproleselan plus chemotherapy in the Phase I/II trial experienced grade 3-4 mucositis, which is remarkably low er than expected based on 
historically observed rates of 10- 30% for the chemotherapy agents 
administered ([STUDY_ID_REMOVED])
34. Furthermore, this clinical observation is 
supported by the nonclinical pharmacology data for uproleselan in mucositis animal models
23. Of note, in a Phase I open -label study evaluating 
uproleselan as a chemo -sensitizing agent added to proteasome -based 
chemotherapy regimens in multiple myeloma patients, E -selectin inhibition 
with uproleselan was found to be relatively safe and well -tolera ted 
([STUDY_ID_REMOVED])34.  
 
Therefore, considering the frequent prevalence of MM, the pivotal therapeutic role of high- dose chemotherapy with rescue auto -HCT and the 
high rates of AEs associated with this treatment approach, these data are 
sufficient to warrant further evaluation of uproleselan as a prophylactic supportive -care therapy to reduce conditioning regimen- associated GI 
toxicity and improve patient QoL, while potentially decreasing healthcare resource utilization and improving outcomes. 
 
1.1.7 Hypothesis  
 
We hypothesize that prophylactic E -selectin inhibition via administration of 
uproleselan during melphalan conditioning will reduce the GI toxicity in MM patients undergoing auto -transplant, as assessed via diarrhea se verity scoring per 
CTCAE v5.0 , while potentially increasing chemosensitivity of malignant MM cells 
to high- dose melphalan.  
 
1.1.8 Correlative Studies Background  
 
Testing of MRD status on routine bone marrow assessments following auto- HCT) 
has become standard of care. We propose  assessment of MRD status at screening 
pre-HCT and D+100 post -transplant in all patients, as post -HCT MRD negativity 
has been correlated wit h improved survival in multiple studies
36-37. We will also 
monitor for PFS and OS  to confirm if these are associated with MRD status in this 
cohort. Soluble E -selectin levels will be measured in order to confirm on- target 
effect of the drug, as previously described34. Based on the mechanism of action of 
uproleselan, w e are also interested in an interdisciplinary collaboration assessing 
biomarkers of GI epithelial injury including fecal calprotectin , fecal lipocalin -2 and 
potentially additional biomarkers  such as neopterin . Calprotectin, a neutrophil -
Version 0 3/22/2022  page 17 of 63 derived S100A8- S100A9 dimer is extensively used as a treatment target in IBD24. 
People with GI GVHD have elevated fecal calprotectin concentrations25, 26. 
Lipocalin- 2 (Lcn -2) is neutrophil gelatinase -associated lipocalin, a pleotropic 
mediator of intestinal and systemic innate immunity27. The function of lipocalin is 
complex, and includes antibacterial and anti -inflammatory effects in the gut, and 
pro-inflammatory effects on extra- intestinal organs such as the liver. Circulating 
lipocalin concentrations correlate with acute and chronic GVHD, and mortality28. 
Neopterin  (from macrophages and T -cells) similarly correlates with disease activity 
in IBD29, 30. Lastly, given the importance of assessing patient reported outcomes in 
clinical trials  and in particular  supportive care trials , we will assess the effect of 
uproleselan on patient reported quality of life . 
 
1.2 Study Design 
 
1.2.1 Overall Design  
 
This is  a Phase II, single- center, randomized, double -blind, placebo- controlled 
clinical trial. Eligible patients undergoing 1st auto-HCT with melphalan 
conditioning for MM will be randomized in a 1:1 allocation to receive either 
prophylactic uproleselan + SOC or  placebo + SOC.  Randomization will be 
stratified by age ≥65 years and <65 years, due to the known increased frequency of 
GI toxicity in elderly populations.  
 
1.2.2 Scientific Rationale for Study Design  
 
Considering the frequent prevalence of MM, the pivotal therapeutic role of high-
dose chemotherapy with rescue auto -HCT and the high rates of AEs associated with 
this treatment approach, further evaluation of uproleselan as a prophylactic therapy 
to reduce c onditioning regimen- associated GI toxicity , improve patient QoL, 
decrease  healthcare resource utilization and improve  outcomes  is warranted. Phase 
I data are available to guide safety and dosing. Therefore, this trial is designed as a Phase II study to evaluate the RP2D dose for efficacy, safety and tolerability. All 
patients will receive SOC prophylaxis with cryotherapy per institutional protocol. Given the lack of additional, highly effective prophylactic strategies, randomization 
to placebo versus investigational treatment is a rational approach. Furthermore, 
given the inherent challenges associated with assessments of diarrhea severity 
along with the potential for  multiple  confounding variables, randomization, double -
blinding and placebo -control are n ecessary design elements.  
 
1.2.3 Justification for Dose  
 
Based on the initial Phase I  pharmacokinetic  and safety  data showing clearance of 
uproleselan is not based on body size and in keeping with the dosing approach in 
the Phase II AML study, we propose using a  fixed dose of uproleselan (GMI -1271) 
800mg, administered as an initial intravenous (IV) dose in the PM of D -3, followed 
Version 0 3/22/2022  page 18 of 63 by 800mg IV every 12 hours through the conditioning chemotherapy period (total 
of 6 doses, last dose A M of D -0, 4 hours  prior to HSC in fusion). 
 
1.3 Risk/Benefit Assessment  
 
1.3.1 Known Potential Risks  
 
Uproleselan (GMI -1271)  
Human safety information regarding uproleselan is available from Phase 1 clinical 
trials in healthy volunteers and subjects with MM, and a Phase 1/2 clinical trial in subjects  with AML. Currently, c linical trials for AML, in which uproleselan is used 
as an adjunct to standard chemotherapy are ongoing, including administration 
alone, with cytarabine -based chemotherapy regimens for AML.  To date, no specific 
toxicities, or target organs for toxicity, have been identified thus far in nonclinical studies or in clinical trials for uproleselan.  Non-specific toxicities considered 
treatment- emergent adverse events (TEAEs) ≥Grade 3  were observed in 34/102 
(33.3%) patients across the afore mentioned studies. Hematologic AEs  
(neutropenia, anemia and thrombocytopenia)  were most commonly observed, 
accounting for 25/102 of the ≥Grade 3  TEAEs and typically occurring with co -
administration of chemotherapy regimens also associated with myelosuppression. Please see IB Table 7 -1 for full table listing all observed TEAEs, along with IB 
Section 7.9 for overlap with expected AEs associated with concurrent  
chemotherapy regimens administered
34. 
 
High -dose Melphalan and Rescue Auto -HCT 
Melphalan is a commonly used chemotherapy, administered in high -doses as a 
conditioning regimen prior to rescue auto- HCT in the treatment of MM. Commonly 
observed toxicities wi th melphalan are detailed in Table 1. Auto-HCT in MM is 
associated with a one -year non- relapse related  mortality of 2 %. All appropriate 
standard of care interventions will be undertaken to manage these associated risks 
and toxicities.  
 
 
   
 
 
  
 
 
 
Version 0 3/22/2022  page 19 of 63 1.3.2 Table 1 Non-Hematologic Adverse Reactions in ≥25% of Patients with 
Multiple Myeloma Who Received Melphalan Conditioning for Auto -
HCT 
 
 
1.3.3 Known Potential Benefits  
 
Uproleselan (GMI -1271)  
The efficacy of uproleselan as prophylaxis for GI -toxicity or as a chemo -sensi tizing 
agent has not been established . However, pre-clinical trials suggest that 
chemotherapy- induced mucositis and neutropenia may be associated with E -
selectin up -regulation, while E -selectin inhibition with uproleselan as an adjunct to 
chemotherapy prot ected mice from weight loss and chemotherapy induced GI 
toxicity while also enhancing neutrophil recovery23. Importantly, the administration 
of uproleselan effectively blocked secondary migration of inflammatory F4/80+ Ly-6C+ macrophages to intestines of m ice following chemotherapy as one 
mechanism of reduced GI toxicity. To date, uproleselan has been evaluated in clinical trials for acute myeloid leukemia (AML) and MM as a potential chemo -
sensitizing agent with an acceptable safety, pharmacokinetic (PK), pharmacodynamic (PD) profile. Additionally, data from these trials demonstrated a low incidence and severity of mucositis in patients administered uproleselan
34. 
Therefore, the potential benefits of uproleselan may include reduced trafficking of inflammatory cells to the GI epithelium  leading to reduced conditioning regimen-
associated GI toxicity and improved patient QoL. Meanwhile, uproleselan may also 
increase MM cell chemosensitivity, leading to improved treatment response to 
high- dose melphala n and improved long- term outcomes . 

Version 0 3/22/2022  page 20 of 63  
High -dose Melphalan and Rescue Auto -HCT 
In the 1980s, high- dose chemotherapy and stem -cell rescue therapy via autologous 
hematopoietic cell transplantation (auto -HCT) was introduced. High -dose 
melphalan is the standard conditioning regimen prior to rescue auto -HCT in the 
treatment of MM.  Randomized trials evaluating melphalan conditioning followed 
by auto- HCT for the treatment of MM have  been shown to improve event free 
survival compared to conventional chemotherapy alone in patients with standard -
risk MM, while lengthening the time patients are without symptoms, treatment and long- term treatment toxicity
6-8.  
 
 
2.0 OBJECTIVES AND ENDPOINTS  
 
Objectives  Endpoints  
Primary  
To demonstrate the superiority of 
prophylactic uproleselan (GMI -1271) plus 
standard of care (SOC) compared to 
placebo plus SOC to reduce diarrhea 
severity in patients receiving high -dose 
melphalan conditioning in preparation for 
auto-HCT in MM.  Change in diarrhea severity, assessed per CTCAE 
v5.0, in patients receiving high- dose melphalan 
conditioning in preparation for auto- HCT for MM  
who receive prophylactic uproleselan (GMI -1271) 
plus standard of care (SOC) compared to placebo 
plus SOC.  
Secondary  
• To demonstrate the superiority of 
prophylactic uproleselan (GMI -1271) 
plus SOC compared to placebo plus 
SOC to:  
o Reduce mucositis severity  
o Reduce alternative GI toxicities 
(e.g. esophagitis, enterocolitis, 
etc.) 
• To descriptively assess the effects of 
prophylactic uproleselan (GMI -1271) 
plus SOC compared to placebo plus 
SOC on:  
o Time to engraftment  
o hospital length of stay (LOS)  
o Use of anti -diarrheal and pain 
medications  
o Patient nutritional status pre -
conditioning and post -HCT  
o Change in Bristol Stool Scale  
o Incidence of post -HCT 
infection prior to engraftment  • Change in mucositis severity, per CTCAE v5.0 
Oral Mucositis criteria  
• Change in alternative GI toxicities (e.g. 
esophagitis, enterocolitis, etc; per CTCAE v5.0)  
• Time to neutrophil engraftment defined as ANC 
≥0.5 x 109/L for 3 consecutive days or ≥1.0 x 
109/L for 1 day 
• Duration of hospital length of stay (LOS), from date of admission for auto-
HCT to date of 
discharge  
• Quantitative use of anti -diarrheal medications 
(loperamide, diphenoxylate, etc.) and pain 
medications (e.g. opioids converted to morphine equivalents)  
• Patient nutritional status  before conditioning and 
at D+14 or date of discharge (whichever is 
sooner), as assessed by total TPN days and 
change in standing weight comparing D -3, D+8 
and date of discharge or D+14 (whichever is 
sooner)  
• Change in Bristol Stool Scale, assessed daily 
(see Appendix D)  
Version 0 3/22/2022  page 21 of 63 • To descriptively assess the effects of 
prophylactic uproleselan (GMI -1271) 
plus SOC compared to placebo plus 
SOC on PRO and QoL related to GI 
toxicity, on D -3, D+8 and date of 
discharge or D+14 (whichever is 
sooner)  
 • Incidence of infection assessed by rates of 
bacteremia (with organism reported when 
available), time to first antibiotics and c. diff  
infections  
• PRO and QoL, per the CTCAE PRO Form v1.0 
with items selected for relevance to GI toxicity and pa tient QoL (see Supplement 1), assessed on 
D-
3, D+8 and date of discharge or D+14 
(whichever is sooner)  
Exploratory  
• To descriptively assess the effects of 
prophylactic uproleselan (GMI -1271) 
plus SOC compared to placebo plus 
SOC on:  
o Minimal Residual Disease (MRD) at 100 days post -HCT  
o Soluble E -selectin levels at pre -
dose (D -3) and post -
conditioning (D -0) time points  
o Progression Free Survival 
(PFS)  
o Overall Survival (OS) 
• To descriptively assess biomarkers of 
GI inflammation  and GI epithelial 
injury, in  collaboration with the 
Division of Gastroenterology • Post-HCT Minimal Residual Disease (MRD) 
testing  at D+100 via ImmunoSeq B -cell receptor 
sequencing (Adaptive Biotechnologies)  
• Soluble E -selectin levels by ELISA assay at pre-
dose (D -3) and post -conditioning (D -0) time 
points  
• Progression Free Survival (PFS) with up to 2 -
year follow up assessed by time -to event 
(Kaplan -Meier analysis)  
• Overall Survival (OS) with up to 2 -year follow 
up assessed by time- to event (Kaplan- Meier 
analysis)  
• Fecal calp rotectin and neutrophil gelatinase -
associated lipocalin -2 (lipocalin -2) biomarkers 
(Tarr Lab) on D -3, D0, D+8 and date of 
discharge or D+14 (whichever is sooner)  
 
 
3.0 STUDY POPULATION 
 
3.1 Inclusion Criteria  
 
1. Biopsy- confirmed multiple myeloma (MM) (per IMWG criteria).  
 
2. Undergoing first auto-HCT for MM  in first partial response (PR)  or better  (see 
Section 11.0 ).  
 
3. Conditioning regimen to be single  agent m elphalan (200 mg/m2) 
 
4. Adults 18 to  75 years of age , inclusive  
 
5. ECOG performance status ≤  2 (see Appendix A )  
 
6. Mobilized ≥  5.0 x 106 CD34+ cells/kg (i.e. sufficient CD34+ HSCs for one auto-
HCT, with at least one  back -up graft in reserve ) 
 
Version 0 3/22/2022  page 22 of 63 7. Adequate  bone marrow and organ function prior to stem cell mobilization, as defined 
below:  
a. Leukocytes , absolute neutrophil count, and platelets all within institutional standard 
limits for high -dose melphalan autologous stem cell transplant  
b. Total bilirubin  ≤ 1.5 x ULN  (unless the patient has a history of Gilbert’s Syndrome, 
in which case, total bilirubin must be ≤  2.5 times the ULN)  
c. AST(SGOT)/ALT(SGPT)  ≤ 3.0 x ULN  
d. Creatinine clearance ≥  30 mL/min  by Cockcroft -Gault  
e. Baseline pulmonary function test ( PFT) with  carbon monoxide diffusion capacity 
in the lung (DLCO)  ≥ 50% and  forced  expiratory volume in 1 second ( FEV1 ) both 
within institutional standard limits for high -dose melphalan autologous stem cell 
transplant  
 
8. The effects of uproleselan (GMI -1271)  on the developing human fetus are unknown.  
For this reason, w omen of childbearing potential and men must agree to use adequate 
contraception (hormonal or barrier method of birth control, prior sterilization 
procedure, abstinence, etc. ) prior to study entry , for the duration of study participation  
and for 12 weeks af ter the completion of the study .  Should a woman become 
pregnant  or suspect she is pregnant while participating in this study, she must  inform 
her treating physician immediately.   Should a man who is participating in the study 
become aware that he has impr egnated a partner, he must inform his treating 
physician immediately.  
 
9. Ability  to understand and willing ness to sign a n IRB approved written informed 
consent document  (or that of legally authorized representative, if applicable).  
 
3.2 Exclusion Criteria  
 
1. A history of other malignancy with the exception of malignancies for which all 
treatment was completed at least 2 years before registration and the patient has no evidence of disease.  
 
2. Active signs or symptoms of CNS involvement by malignancy (lumbar puncture not required). Prior history of CNS involvement is acceptable , if patient has completed 
treatment for CNS involvement with documented treatment response .  
 
3. Prior exposure to uproleselan (GMI -1271)   
 
4. Currently receiving any other investigational agents  
 
5. A history of allergic reactions attributed to compounds of similar chemical or biologic 
composition to uproleselan or melphalan  
 
6. Known active infection with hepatitis A, B (e.g., HBsAg positive), or C (e.g., anti -HCV 
positive), or human immunodeficiency virus  
 
Version 0 3/22/2022  page 23 of 63 7. Uncontrolled acute life -threatening bacterial, viral, or fungal infection  
 
8. Myocardial infarction within 6 months of uproleselan/placebo dosing, or subject has 
current significant cardiovascular disease, such as uncontrolled or symptomatic arrhythmias, co ngestive heart failure, hemodynamic instability, or any Class 3 or  
4 cardiac disease as defined by the New York Heart Association Functional Classification  
 
9. Any medical, psychiatric, or other condition which, in the opinion of the investigator, unfavorably  alters the risk -benefit of subject participation, is likely to interfere with 
trial completion, assessments, or interpretation of trial results, or otherwise would make the subject an inappropriate subject for this trial.  
 
10. Pregnant  and/or breastfeeding.   
 
11. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless  they are using highly effective contraception during the trial 
and for 12 weeks following the last dose of uproleselan/placebo. Women who are postmenopausal with amenorrhea for at least 1 year prior to trial entry and follicle 
stimulating hormone (FSH) serum levels consistent with postmenopausal status (>28U/L) will be considered NOT of childbearing potential. Highly effective contraception include s: 
a. Total abstinence with a male partner.  
b. Female sterilization (has had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before uproleselan/placebo. In case 
of oophorectomy alone, the subject would be eligible  only when the reproductive 
status of the woman has been confirmed by follow up hormone level assessment.  
c. Male sterilization (at least 6 months prior to Screening). For female subjects on the 
trial, the vasectomized male partner should be the sole partner for that subject.  
d. BOTH of the following forms of contraception consistently used together:  
i. Injected, transdermal, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%) with the exception of intrauterine devices, which are excluded due to the risk of infection and bleeding. 
ii. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with or without spermicidal foam/gel/film/cream/vaginal suppos itory.  
iii. Men who are sexually active and not  willing to use condoms during the trial 
and for 12 weeks following the last dose of uproleselan/placebo, unless they have undergone vasectomy for sterilization (at least 6 months prior to Screening), are excluded from trial participation.  
 
12. Men who are sexually active and not  willing to use condoms during the trial and for 
12 weeks following the last dose of uproleselan/placebo, unless they have undergone vasectomy for sterilization (at least 6 months prior to Scree ning), are excluded from 
trial participation.  
Version 0 3/22/2022  page 24 of 63  
3.3 Inclusion of Women and Minorities  
 
Both men and women and members of all races and ethnic groups are eligible for this trial.   
 
 
4.0 REGISTRATION PROCEDURES  
 Patients must not start any protocol intervention  prior to registration through the Siteman 
Cancer Center.  
 
The following steps must be taken before registering patients to this study:  
 
1. Confirmation of patient eligibility   
2. Registration of patient in the Siteman Cancer Center database  
3. Assignment of unique  patient number (UPN) 
 
4.1 Confirmation of Patient Eligibility  
 
Confirm patient eligibility by collecting  the information listed  
1. The registering MD’s name  
2. Patient’s race, sex, and DOB  
3. Three letters (or two letters and a dash) for the patient’s initials  
4. Copy of signed consent form   
5. Completed eligibility checklist, signed and dated by a member of the study team  
6. Copy of appropriate source documentation confirming patient eligibility  
 
4.2 Patient Registration in the Siteman Cancer Center OnCore Database  
 All p atients must be registered through the Siteman Cancer Center OnCore dat abase.  
 
4.3 Assignment of UPN  
 
Each patient will be identified with a unique patient number (UPN) for this study.  All data will be recorded with this identification number on the appropriate CRFs. 
 
4.4 Screen Failures 
 
Screen failures are defined as partici pants who c onsent to participate in the clinical trial 
but are not subsequently randomized to the study intervention or entered in the study.  A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requi rements and to respond to queries from regulatory 
authorities.  Minimal information includes demography, screen failure details, eligibility 
criteria, and any serious adverse event (if applicable).   
 
Version 0 3/22/2022  page 25 of 63  
4.5 Measures to Minimize Bias:  Randomization and Blinding  
 
4.5.1 Randomization  
 
Fifty  patients with MM will be randomized in a 1:1 allocation to receive either 
uproleselan pl us SOC or placebo plus SOC as GI -toxicity prophylaxis during 
melphalan conditioning prior to auto -HCT.  Randomization will be stratified by age 
≥65 years and <65 years, due to increased frequency of GI toxicity in elderly 
populations.   The randomization ta ble will be generated using the SAS program 
PROC PLAN. To  better  ensure  the balance of patient  characteristics across two 
arms,  treatment  assignment  will be implemented  in small  blocks  of 4 or 6  patients.  
Enrollment will continue until 50 evaluable patients are enrolled. Randomization 
will occur following registration and implemented with the OnCore system.  
 After the Screening evaluations have been performed and a patient is confirmed to be eligible for s tudy, they will be to a treatment group. 
 The Interactive Web Response System ( IWRS ) will provide the designated 
unblinded investigational pharmacist the subject’s treatment assignment. Dose 
preparation procedures will be performed by the pharmacist utiliz ing uproleselan 
or placebo provided by GlycoMimetics . 
 Treatment assignment received at randomization will be maintained throughout the conditioning period.  
 
4.5.2 Blinding  
 
This trial will be double -blinded and placebo -controlled. All healthcare providers, 
ancillary support staff, research support staff and patients participating in  the trial 
will remain blinded to treatment, including personnel at GlycoMimetics. The 
investigational pharmacists participating in the study will be unblinded to treatment  
assign ments . Investigational drug or placebo will be IV saline solution, provided 
by the  investigational pharmacy in a blinded manner to the non- pharmacy study 
personnel  for administration to trial patients, based on the patients’ treatment 
assignment at randomi zation.  
 The blind will be maintained for treatment assignment for randomized subjects until  
30 days after the last patient has completed HCT  and has been fully assessed for 
the primary endpoint of the study.  
 The blind will be maintained in the following manner:  
• The investigational pharmacist (or authorized designee) will be unblinded 
and will prepare uproleselan and placebo in a blinded manner in order to maintain the blind for all other trial personnel.  
Version 0 3/22/2022  page 26 of 63 • Unblinding may only be performed in emergencies where knowledge of the 
subject’s treatment assignment is essential for immediate management of the subject’s medical care. It is anticipated that such situations will be extremely rare. If the treatment of the AE/safety issue is the same regardless of the tr eatment assignment, the blind should not be broken. Unblinding a 
subject’s treatment assignment by the investigator under any other circumstances will be considered a protocol violation.  
• Subjects whose treatment assignment is unblinded will continue all tr ial 
treatment and assessments per protocol.  
• Any intentional or unintentional unblinding events must be reported to the 
Principal Investigator (PI ) immediately and also documented in the medical 
record , including: date, time, and reason for breaking the blind . 
• Treatment randomization information, and any analytical results will be kept confidential and will not be released to the investigator or blinded personnel until the conclusion of the trial.  
 
4.6 Replacement of Patients  
 
Patients who are screened, found  to be eligible, and randomized to a treatment arm but who 
subsequently do not undergo auto -HCT or are removed from the study prior to receiving 
study- related treatments are not evaluable for the primary endpoint and therefore will be 
replaced in order to achieve the target enrollment of 50 evaluable patients.  
  
5.0 TREATMENT PLAN  
 
5.1 Study Intervention Description 
 
Following consent, patients will undergo all screening procedures , and those meeting 
eligibility requirements will be randomized as described in Section 4.5.1 to either uproleselan + SOC or placebo + SOC. All patients will be admitted to the hospital 3 days (Day -3) prior to the scheduled date of HSC infusion (D ay 0).  
 
• On the evening of D ay -3, patients will receive dose #1 of uproleselan or placebo  
(suggested dosing time is 8:00pm) .  
• On the following morning of D ay -2 (12 +/ - 2 hours from prior dose) , patient s will 
receive dose #2 of uproleselan or placebo.  
• On the evening of D ay -2 (12 +/ - 2 hours from prior dose), patients wi ll receive 
dose #3 of uproleselan or placebo.  
• On Day  -2 following completion of dose #3 of uproleselan or placebo, the patient 
will be administered the conditioning dose of melphalan (200mg/m
2) as per 
institutional practice .  
• On the  following morning of D ay -1 (12 +/ - 2 hours from prior dose) , patient s will 
receive dose #4 of uproleselan or placebo.  
• On the evening of D ay -1 (12 +/ - 2 hours from prior dose), patients will receive 
dose #5 of uproleselan or placebo.  
Version 0 3/22/2022  page 27 of 63 • On the following morning of D ay 0 (12 +/ - 2 hours from prior dose) patient s will 
receive dose #6 (final dose) of uproleselan or placebo.  
• On Day 0, 4 hours (+/ - 2 hours) after the final dose of uproleselan or placebo, the 
patient will be infused with the HSC product. The patient will remain in patient until 
engraftment and will follow -up for study assessments per the full schedule of 
assessments.  
 
5.1.1 Uproleselan (GMI -1271)  and Placebo Preparation and Dosing  
 
Uproleselan injection, 50 mg/mL  is supplied in single -dose vials at a concentration 
of 50 mg/mL.  Uproleselan injection 50 mg/mL is stored per the specified 
conditions on the label, frozen ( 10 °C to - 25 °C)  prior to administration.  The frozen 
product can appear as a homogenous solid, a striated solid, or as a super -cooled 
liquid.  When using frozen supply,  vials should be brought to room temperature 
before dose preparation.  Upon thawing, the product should be gently inverted 4 to 
5 times to ensure homogeneity of the solution.  The thawed solution is clear, 
colorless to slightly yellow, and free from visible particulates.    Uproleselan should be administered IV into a peripheral line, a central catheter, or a peripherally inserted ce ntral line catheter (PICC). Infusion should take place at a 
steady rate over a period of 20 minutes ( +/-2 minutes) using a syringe pump or IV 
pump. Microbore tubing is preferred. In- line filtration is highly recommended. 
Dilution of uproleselan may be perf ormed with normal saline (0.9% Sodium 
Chloride).  
 
Compatibility with other therapeutic agents has not been determined; therefore, uproleselan injection should be administered via a separate IV line and should not be administered concurrently with anything other than saline.  If a flush is used, 
saline flush is preferred.  
 When prepared in syringes or intravenous (IV) bags without an administration set attached, uproleselan may be stored refrigerated up to 72 hours prior to administration or up to 24 hours at controlled room temperature prior to administration.  Administration sets manufactured from materials of construction other than polyvinyl chloride (PVC) with di(2 -ethylhexyl)phthalate (DEHP) can be 
primed up to 72 hours before dosing if stored refriger ated or up to 24 hours before 
dosing if stored at controlled room temperature.  Intravenous lines consisting of PVC with DEHP should be avoided when possible.  If PVC with DEHP administration sets must be used they should be primed with uproleselan solution no more than 2 hours before dosing.  It is highly recommended that uproleselan prepared prior to administration be refrigerated until 1 hour prior to dosing.  
 Uproleselan (GMI -1271) will be given as a single dose at 800 mg, administered as 
an initial int ravenous (IV) dose in the evening of Day -3, followed by 800 mg IV 
every 12 hours through the conditioning chemotherapy period (total of 6 doses, last dose AM of D ay 0 prior to HSC infusion). Three  doses of uproleselan should be 
Version 0 3/22/2022  page 28 of 63 administered prior to admin istration of the melphalan conditioning regimen, with 3 
doses administered following administration of the melphalan conditioning 
regimen.  As placebo, c ommercially available saline (0.9% Sodium Chloride Injection) will 
be prepared by the site’s pharmacist  in IV administration components (syringe, bag, 
tubing, etc.) matching those used for active treatment to maintain the blind. The dosing schedule and procedure for placebo will be identical to that for uproleselan. It is recommended that placebo prepared p rior to administration be refrigerated 
until one hour prior to dosing, to match pharmacy procedures for uproleselan. Preparation of placebo in advance of administration should be in accordance with institutional pharmacy standards and commercial label for the placebo control . 
 
5.1.2 Melphalan Dosing  
 
Melphalan will be administered as a single, IV dose  at 200 mg/m2 infused over 20 
minutes on HCT Day - 2, with the following guidance:  
o Dosing instructions:  
 If actual Body Weight (BW) is less than ideal BW, use actual BW  
 If actual BW is greater than ideal BW, but less than 120% of ideal BW, 
use ideal BW 
 If actual BW is greater than or equal to 120% of ideal BW, use corrected 
BW 
• Corrected BW = ([actual BW – ideal BW] x 0.2) + ideal BW  
o Dose rounding:  
 Dosing will be rounde d to the nearest 50mg provided that the dose is 
within 5% of the calculated dose, as above  
o Dose a dministration:  
 Melphalan will be administered as per instructional practice and 
guidelines, which is typically at 9PM.  
 
5.2 Definitions of Evaluability  
 
All patients who receive any study treatment are evaluable for toxicity.  Patients are 
evaluated from first receiving study treatment until a 30- day follow up after the conclusion 
of treatment or death.  
 All patients who receive at least one dose of uproleselan or placebo and undergo auto -HCT 
are evaluable for disease response unless they  are removed from the study prior to 
undergoing any study- related disease response assessment.    Patients who do not undergo 
auto- HCT or are removed from the study prior to rec eive study -related treatments will be 
replaced.  
 
 
  
Version 0 3/22/2022  page 29 of 63 5.3 Concomitant Therapy  and Supportive Care Guidelines  
 
At Trial Start: Prior G -CSF, granulocyte macrophage -colony stimulating factor (GM -
CSF) or plerixafor is prohibited within 3 days prior to  uproleselan/placebo dosing.  
 
GI Toxicity Prophylaxis:  SOC cryotherapy will be provided to all patients for GI -toxicity 
prophylaxis , per institutional practice . 
 Post-auto -HCT:  G-CSF may not be initiated until 72 hours after the last dose of 
uproleselan/pl acebo in each cycle. The use of erythropoiesis -stimulating agents such as 
epoetin and darbepoetin is not allowed.  Supportive Care:  All additional and medically indicated supportive cares, including pain 
medications, anti -diarrheal medications, antimicrobials and any other indicated palliative 
therapy will be available and provided to the patients, per institutional practice and best standards of care.  
 
5.4 Women of Childbearing Potential  
 
Women of childbearing potential (defined as women with regular menses, w omen  with 
amenorrhea, women with irregular cycles, women using a contraceptive method that 
precludes withdrawal bleeding , and w omen who have had a tubal ligation ) are required to 
have a negative serum/urine pregnancy test at screening and again on D ay -3 prior to the 
first dose of uproleselan /placebo.  Women who are postmenopausal with amenorrhea for 
at least 1 year prior to trial entry and follicle stimulating hormone (FSH) serum levels 
consistent with postmenopausal status (>28U/L) will be considered NOT  of childbearing 
potential.  
 
Female and male patients (along with their female partners) are required to use highly effective contraception  during participation in the study and for at least 12 weeks following 
the last dose  of uproleselan /placebo.  Highly effective contraception includes:  
a. Total abstinence with a male partner.  
b. Female sterilization (surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before uproleselan/placebo  
c. Male sterilization (at least 6 months  prior to Screening). For female subjects on the 
trial, the vasectomized male partner should be the sole partner for that subject.  
d. BOTH of the following forms of contraception consistently used together:  
i. Injected, transdermal, or implanted hormonal methods  of contraception or 
other forms of hormonal contraception that have comparable efficacy (failure rate <1%) with the exception of intrauterine devices, which are excluded due to the risk of infection and bleeding. 
ii. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with or without spermicidal foam/gel/film/cream/vaginal suppository.  
 
Version 0 3/22/2022  page 30 of 63 If a patient is suspected to be pregnant, uproleselan /placebo  should be immediately 
discontinued. In addition,  a positive urine test mu st be confirmed by a serum pregnancy 
test.  If it is confirmed that the patient is not pregnant, the patient may resume dosing.  
 
If a female patient or female partner of a male patient becomes pregnant during therapy or within 12 weeks  after the last dose of uproleselan /placebo , the investigator must be notified 
in order to facilitate outcome follow -up. 
 
5.5 Duration of Therapy  
 
If at any time the constraints of this protocol are considered to be detrimental to the patient’s health and/or the patient no longer wishes to c ontinue protocol therapy, the 
protocol therapy should be discontinued and the reason(s) for discontinuation documented in the case report forms.  
 In the absence of treatment delays due to adverse events, treatment may continue for  6 
doses  of upr oleselan or place bo or until one of the following criteria applies:  
 
• Documented and confirmed disease progression  
• Death  
• Adverse event(s) that, in the judgment  of the investigator, may cause severe or 
permanent harm or which rule out continuation of study drug 
• General or specific changes in the patient’s condition render the patient unable to receive further treatment in the judgment  of the investigator  
• Suspected pregnancy  
• Serious noncompliance with the study protocol  
• Lost to follow -up 
• Patient withdraws consent  
• Investigator removes the patient from study  
• The Siteman Cancer Center decides to close the study  
 
Patients who prematurely discontinue treatment for any reason will still be followed as 
indicated in the study calendar . 
 
5.6 Duration of Follow -up 
 
Patie nts will be followed at D+30, D+100, 6 months, and 12 months  with SOC assessments 
per institutional practice. Of note, the  D+100 bone marrow assessment will include a bone 
marrow sample sent for MRD testing . Following that , patients will be contacted by phone 
every 3-6 months to assess for PFS and OS for an additional year ( ending at 2 years post-
HCT ).  Patients removed from study for unacceptable adverse events will be followed until 
resolution  or stabilization of the adverse event.   
    
Version 0 3/22/2022  page 31 of 63 5.7 Lost to Follow -Up 
 
A participant will be considered lost to follow -up if he or she fails to return for 6 weeks 
following a  scheduled visit and is unable to be contacted by the study team.  
 
The following actions must be taken if the participant fails to return to clinic for  a required 
study visit:  
o The study team will attempt to contact the participant and reschedule the missed visit within  6 weeks and counsel the participant on the importance of maintainin g 
the assigned visit schedule and ascertain if the participant wishes to and/or should continue in the study.  
o Before a participant is deemed lost to follow -up, the investigator or designee will 
make every effor t to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to  the participant’s last known mailing 
address).  These contact attemp ts should be documented in the participant’s medical 
record or study file.  
o Should the participant continue to be unreachable, he or she will be considered to have withdrawn from the study with a primary reason of lost to follow -up. 
  
6.0 DOSE DELAYS/DOSE MODIFICATIONS  
 
No dose modifications are recommended for uproleselan/placebo, nor should dose modifications 
be made without direct consultation with the PI. Dose delays should only occur in the event of a medical emergency , and the PI should be made aware of any anticipated deviations from the dosing 
protocol given the importance of timely administration of uproleselan concurrent with melphalan  
(3 doses of uproleselan prior to melphalan adminis tration and 3 doses following melphalan) , as 
well as the completion of the sixth and final  dose of uproleselan/placebo 4 hours (+/ - 2 hours) prior 
to the HSC infusion. 
  
7.0 REGULATORY AND REPORTING REQUIREMENTS  
 
The entities providing oversight of safety and compliance with the protocol require reporting as 
outline d below.  Please refer to Appendix B for definitions and Appendix C for a grid of reporting 
timelines.  
 
Adverse events will be tracked from start of treatment through  D+30 post auto- HCT .  All adverse  
events must be recorded on the toxicity tracking case report form (CRF) with the exception of:  
• Baseline adverse events, which shall be recorded on the medical history CRF  
• AEs related to the initial induction chemotherapy and mobilization  
 
AEs related to  the conditioning regimen (melphalan) and auto- HCT should be recorded in the 
CRF, given the primary outcome being reduction in chemotherapy- related GI toxicities . 
 
Version 0 3/22/2022  page 32 of 63 Refer to the data submission schedule in Section 10 for instructions on the collection of AEs  in the 
EDC.  
 
Reporting requirements for Washington University study team may be found in Section 7.1.      
7.1 Sponsor -Investigator Reporting Requirements 
 
7.1.1 Reporting to the Human Research Protection Office (HRPO) at Washington University  
 
Reporting will be conducted in accordance with Washington University IRB 
Policies.  
 
Pre-approval of all protocol exceptions must be obtained prior to implementing the 
change . 
 
7.1.2 Reporting to the Quality Assurance and Safety Monitoring Committee (QASMC) at Washington University  
 
The Sponsor Investigator  (or designee) is required to notify the QASMC of any 
unanticipated problem s involving risks to participants or others  occurring at WU or 
any BJH or SLCH institution that has been reported to and acknowledged by HRPO.  (Unanticip ated problems reported to HRPO and withdrawn during the 
review process need not be reported to QASMC.)  
 QASMC must be notified within 10 days  of receipt of IRB acknowledgment via 
email to qasmc@wustl.edu
.  Submission to QASMC must include the myIRB form 
and any supporting documentation sent with the form.  
 
7.1.3 Reporting to Glyco Mimetics, Inc.  
 According to the timelines referenced in Appendix C, the Sponsor shall use commercially reasonable efforts to forward assessed case information regarding 
SAEs and other safety information that it receives from a patient receiving the investigational product or placebo.  
 
7.1.4 Reporting to the FDA  
 
The conduct of the study will comply with all FDA safety reporting requirements.  PLEASE NOTE THAT REPORTING REQUIREMENTS FOR THE FDA 
DIFFER FROM REPORTING REQUIREMENTS FOR HRPO/QASMC.  It 
is the responsibility of the Sponsor -Investigator to report to the FDA as follows:  
 
Version 0 3/22/2022  page 33 of 63 • Report any unexpected fatal or life -threatening suspected adverse  reaction  
(refer to Appendix B for definitions) no later than 7 calendar days  after 
initial receipt of the information.   
• Report a  suspected  adverse reaction that is both serious and unexpected 
(SUSAR, refer to Appendix B) no later than 15 calendar days  after it is 
determined that the information qualifies for reporting.  Report an adverse 
event (refer to Appendix B ) as a suspected adverse reaction only if there is 
evidence to suggest a causal relationship between the drug and the adverse event, such as:  
o A single occurrence of an event that is uncommon and known to be 
strongly associated with drug exposure  
o One or more occurrences of an event that is not commonly associated 
with drug exposure but is otherwise uncommon in the population exposed to the drug  
o An aggregate analysis of specific events observed in a clinical trial that indicates those events occur more frequently in the drug treatment group than in a concurrent or historical control group 
• Report any findings from epidemiological studies, pooled analysis of 
multiple studies, or clinical studies that suggest a significant risk in humans 
exposed to the drug no later than 15 calendar days  after it is determined 
that the information qualifies for reporting.  
• Report any findings from animal or in vitro testing that suggest significant risk in humans exposed to the drug no later than 15 calendar days  after it 
is determined that the information qualifies for reporting.   
• Report any clinically important increase in the rate of a serious suspected 
adverse reaction  of that listed in the protocol or IB within 15 calendar days  
after it is determined that the information qualifies for reporting.  
 Submit each report as an IND safety report in a narrative format or on FDA Form 3500A or in an electronic format that FDA ca n process, review, and archive.  Study 
teams must notify the Siteman Cancer Center Protocol Development team of each potentially reportable event within 1 business day after initial receipt of the information, and must bring the signed 1571 and FDA Form 3500A to the Siteman Cancer Center Protocol Development team no later than 1 business day prior to the due date for reporting to the FDA.  Each notification to FDA must bear prominent identification of its contents (“IND Safety Report”) and must be transmitted to the review division in the Center for 
Drug Evaluation and Research (CDER) or in the Center for Biologics Evaluation and Research (CBER) that has responsibility for review of the IND.  Relevant follow -up information to an IND safety report must be submitted as soon as the 
information is available and must be identified as such (“Follow -up IND Safety 
Report”).  
   
Version 0 3/22/2022  page 34 of 63 7.2 Exceptions to Expedited Reporting  
 
Events that do not require expedited reporting as described in Section 7.1 include:  
• planned hospit alizations  
• hospitalizations < 24 hours  
• respite care  
• events related to disease progression  
 
Events that do not require expedited reporting must still be captured in the EDC.  
 
 
8.0 PHARMACEUTICAL INFORMATION  
 
8.1 Uproleselan (GMI -1271)  
 
8.1.1 Uproleselan (GMI -1271) Description  
  
Chemical Name: Sodium (1R , 3R, 4R, 5S)-3-({2-N-acetylamino -2-deoxy -3-O-
[(1S)-1-carboxylato -2-cyclohexylethyl] -β-D-galactopyranosyl}oxy) -4-({6-deoxy-
α-L-galactopyranosyl}oxy) -5-ethyl -cyclohexan -1-yl-(38-oxo-
2,5,8,11,14,17,20,23,26,29, 32,35- dodecaoxa -39-azahentetracontan -41-yl) 
carboxamide  
 Chemical Formula: C60H108N3NaO27   
Molecular Weight: 1326.5  
 
Figure 4 -1. Uproleselan Chemical Structure  
 
 
 
 
8.1.2 Clinical Pharmacology  
 

Version 0 3/22/2022  page 35 of 63 PK evaluations in healthy volunteers showed a dose -linear relationship in mean PK 
parameters after IV infusion of uproleselan 2 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg 
and 40 mg/kg. Uproleselan is characterized by a half -life of 1.4 -2.5 hours and does 
not accum ulate after doses up to 20 mg/kg BID. Population PK analysis in healthy 
volunteers and patients with AML demonstrate similar PK profiles, PK parameters, and dose -proportionality. Clearance was found to depend on renal function and 
have a similar magnitude in both healthy volunteers and in patients with AML. Clearance is not dependent on body size which allows for flat -fixed dosing. The 
PK of uproleselan does not appear to be affected when co- administered with 
chemotherapy.   Absolute CD34+ counts did not increase in peripheral blood after administration of uproleselan.  
 
8.1.3 Pharmacokinetics and Drug Metabolism  
 
A population PK analysis was conducted using data from trial GMI -1271- 201 to 
understand the PK of uproleselan when administered with cytotoxic chemothe rapy 
in patients with AML. This analysis revealed a similar PK profile in these patients and healthy volunteers. It was found that clearance of uproleselan varies with renal function and does not vary with body size or any other covariate evaluated. Minima l 
accumulation of uproleselan at any dose level was observed, as expected from the short half -life.  
 Following from the population PK finding that clearance does not depend on body 
size, conversion to a flat -fixed dose for subsequent trials is appropriate . Exposure -
response analyses further demonstrated that safety and efficacy responses are not dependent on exposure. In the GMI -1271- 201 trial, the majority of patients with 
R/R AML were administered a dose of 10 mg/kg at a median body weight of 82.6 kg. The corresponding flat -fixed dose is 800 mg. Therefore, a flat -fixed dose of 800 
mg will be used  in this trial.  
 
8.1.4 Supplier  
 
Uproleselan will be supplied by GlycoMimetics, Inc. 
 
8.1.5 Dosage Form and Preparation  
 
Uproleselan will be supplied in sterile single -dose vials at a concentration of 50 
mg/mL. The drug product should be stored frozen ( -10°C to - 25°C) or refrigerated 
(2°C to 8°C) per the label directions until time of use. The frozen product can appear as a homogenous solid, a striated solid, or as a super -cooled liquid. Frozen 
drug product should be brought to room temperature before dose preparation. Upon thawing, the product should be gently inverted 4 to 5 times to ensure homogeneity of the solution. The thawed or refrigerated solution is clear, colorless to slightly yellow, and free from visible particulates . 
Version 0 3/22/2022  page 36 of 63 8.1.6 Storage  and Stability  
 
Uproleselan injection 50 mg/mL is stored per the specified conditions on the label, 
either frozen (- 10°C to - 25°C) or refrigerated (2°C to 8°C), prior to administration. 
The frozen product can appear as a homogenous solid, a striated solid, or as a super -
cooled liquid. Frozen vials should be brought to room temperature before dose preparation. Upon thawing, the product should be gently inverted 4 to 5 times to 
ensure homogenei ty of the solution. The thawed or refrigerated solution is clear, 
colorless to slightly yellow, and free from visible particulates. Reconstitution and dilution are not necessary. Dilution up to 5X may be performed with normal saline.  
 When prepared in syr inges or intravenous (IV) bags without an administration set 
attached, uproleselan may be stored refrigerated up to 72 hours prior to administration or up to 24 hours at controlled room temperature prior to administration.  Administration sets manufactured  from materials of construction 
other than polyvinyl chloride (PVC) with di(2 -ethylhexyl)phthalate (DEHP) can be 
primed up to 72 hours before dosing if stored refrigerated or up to 24 hours before dosing if stored at controlled room temperature.  Intravenous lines consisting of PVC with DEHP should be avoided when possible.  If PVC with DEHP administration sets must be used they should be primed with uproleselan solution no more than 2 hours before dosing.  It is highly recommended that uproleselan prepared  prior to administration be refrigerated until 1 hour prior to dosing.   
 The investigational product is to be in a locked and secured storage facility, accessible only to those individuals authorized by the PI.  
 
8.1.7 Administration  
 
Uproleselan injection is a sterile solution for IV administration, supplied in single -
dose vials at a concentration of 50 mg/mL.  
 Uproleselan injection should be administered IV into a peripheral line, a central catheter, or a peripherally inserted centra l line catheter (PICC). Infusion should take 
place at a steady rate over a period of 20 minutes using a syringe pump or IV pump. Microbore tubing is preferred. In- line filtration is highly recommended.  
 Compatibility with other therapeutic agents has not been determined; therefore,  
uproleselan injection should be administered via a separate IV line, and should not be administered concurrently with anything other than saline. If a flush is used, saline flush is preferred.  
 
8.2 Placebo  
 
As placebo, commercially available saline (0.9% Sodium Chloride Injection) will be prepared by the site’s pharmacist in IV administration components (syringe, bag, tubing, etc.) matching those used for active treatment to maintain the blind. The dosing schedule 
Version 0 3/22/2022  page 37 of 63 and procedure for placebo will be identical to that for uproleselan. It is recommended that 
placebo prepared prior to administration be refrigerated until one hour prior to dosing, to match pharmacy procedures for uproleselan. Preparation of placebo in advance of  
administration should be in accordance with institutional pharmacy standards and commercial label for the placebo control . 
   
9.0 CORRELATIVE STUDIES  
 
9.1 Minimal Residual Disease (MRD) Status Following HCT  
 
Post-HCT MRD testing will be performed on the D+100 bone marrow biopsy sample  for 
all patients , with pre -HCT MRD testing during screening as baseline. The MRD testing 
will be performed per SOC and institutional practice as a send -out test via ImmunoSeq B -
cell receptor sequencing (Adaptive Biotechnologies). Standard handling, processing, preserving, and shipping will proceed as per the current institutional practices.  
 
9.1.1 Collection of Specimen(s)  
 Collect 2  mL of bone marrow aspirate (BMA) in an EDTA tube . 
 
9.1.2 Handling of Specimen(s)  
 
• No onsite processing of the specimen is required . 
• The fresh BMA specimen collection and submission kits will include the 
following:  
o One (1) 3 mL EDTA tube for BMA collection  
o One (1) ambient pack  
o One (1) FedEx clinical pack pre -labeled with a FedEx shipping label   
• Store specimen in ambient pack for same day shipment for next day 10 AM PT delivery  
• If same day shipment is not an option, store specimen refrigerated until 
shipment for next day 10 AM PT delivery. Fresh specimens should be 
received at Adaptive within 5 days of collection. 
 
9.1.3 Shipping of Specimen(s)   
 Specimens must be packaged and shipped according to the instructions provided with the specimen kit.   Batch shipping is not allowed.   Specimens must be transported on the same day as collected via express courier (FedEx is recommended) using standard next day delivery service to arrive on 
Monday through Saturday  
Version 0 3/22/2022  page 38 of 63  
For Saturday delivery, be sure to check the Saturday delivery box on the express courier form. If not checked, the courier will deliver on Monday, and the sample will be too old to process.  
 The specimen will be shipped to  Adaptive Biotechnologies : 
Phone: 888- 552-8988 
E-mail: clinicalservices@adaptivebiotech.com  
 
9.2 E-selectin Levels  
 Soluble E -selectin levels will be assessed on D ay -3 prior to administration of uproleselan 
and on D0 following completion of the conditioning regimen and uproleselan dosing, but prior to HSC infusion via ELISA assay.  
 
9.2.1 Collection of Specimen(s)  
 
Collect 3 mL of peripheral blood in a Na Citrate (light blue top) tube . 
 
9.2.2 Handling of Specimen(s)  
 
Samples will be taken to the Washington University Tissue Procurement Core and processed per standard operating procedure. Blood will be drawn into sodium citrate tubes, inverted 3 -4 times and stored in an ice bath until centrifugation. 
Samples will be cen trifuged at 1,300 g at room temperature for 5 minutes. Ideally, 
samples should be immediately centrifuged following collection. If institutional staffing and/or logistics do not allow for this, samples may be stored (via an ice bath or at approximately 4°C ) for 48- 72 hours before centrifugation.   
 After centrifugation, pipette half of plasma into an appropriately labeled cryovial (primary aliquot).  Pipette the remaining plasma into an additional appropriately labeled cryovials (back -up aliquot).  Labels s hould include date and time of 
collection and subject ID/UPN.  
 The aliquots will be placed into a freezer at - 80°C for temporary storage and then 
transferred to stor age in liquid nitrogen vapor until shipped for analysis . 
 
9.2.3 Shipping of Specimen(s)  
 
Samples will be batch -shipped at the completion of the study.  The primary and 
back -up aliquots will be shipped on separate days to mitigate loss (Monday -  
Wednesday only), via overnight carrier with the appropriate amount of dry ice.  
QPS, LLC  
ATTN Sample Coordinator  
1 Innovation Way, Suite 200 Newark, Delaware 19711  
Version 0 3/22/2022  page 39 of 63 Contact: Susan ZONDLO 
E-mail: susan.zondlo@qps.com and tlmsmt@qps.com  
Tel.: + 1 302 453 5911 
 Upon shipment of the samples, an e -mail will be sent containing a sample 
manifest, the name of the courier, the airway bill number, and a confirmation of the number of samples in the shipment.   
 
9.3 GI Epithelial Inflammation and Permeability Biomarkers 
 
Based on the mechanism of action of uproleselan, we are also interested in an interdisciplinary collaboration assessing biomarkers of GI epithelial injury and GI permeability, including fecal calprotectin  and fecal lipocalin -2, as well as other  potential  
exploratory biomarkers  such as neopterin . Fecal samples for  banking will be collected on 
Day -3 (or first available stool), D ay 0 (or Day 1 if not available Day 0) , Day +8 (or Day 9 
if not available Day 0), and D ay +14 or date of discharge (+/ -1 day, whichever is sooner ). 
 
9.3.1 Fecal calprotectin , lipocalin -2 & Stool Biomarker  Banking  
 Collect 15 mL  (minimum 5 mL) of feces/stool in a stool container  to be banked as 
a fecal specimen for later assessment of calprotectin , lipocalin- 2 and other stool 
biomarkers  of inflammation via ELISA assay  (or other assay as indicated) . 
 
Collect a fresh random fecal specimen, no preservative.  
 
Banked fecal specimens will be sent to the Tissue Procurement Core  for frozen 
banking. The total specimen will be divided into 5 aliquots of equal volume. The 5 
aliquots will be placed into a freezer at - 80°C for temporary storage and then 
transferred to storage in liquid nitrogen vapor until shipped for analysis.  
 At the time of specimen analysis, the fecal specimens will be sent out (frozen) to 
Mayo Lab, per standard processing . 
  
10.0 DATA SUBMISSION SCHEDULE 
 
Case report forms with appropriate source documentation will be completed according to the 
schedule listed in this section.  
 
Case Repor t Form  Submission Schedule  
Original Consent Form  Prior to registration  
On-Study Form  
Medical History Form  Prior to starting treatment 
Treatment Form  Completion of treatment  
Version 0 3/22/2022  page 40 of 63 Toxicity Form  Continuous  (start of treatment through Day +30)  
Follow Up Form  Day 30, Day 60, Day 100, Month 6, Month 12, Month 
15, Month 18, Month 21, Month 24  
MRD Form  Day 100  
E-selectin Form  Day -3 
GI Biomarkers Form  
QOL Form  Day -3, Day 0  (GI Biomarkers Form only) , Day 8, Day 
14/DOD  
Progression Form  Time of disease progression  
Death Form  Time of death  
MedWatch Form  See Section 7.0 for reporting requirements  
 
  
10.1 Adverse Event Collection in the Case Report Forms  
 
All adverse events that occur beginning with start of treatment (minus exceptions defined in Section 7.0)  must be captured in the Toxicity Form.  Baseline AEs should be captured 
on the Medical History Form.  
 Participant death due to disease progression should be reported on the Toxicity Form as grade 5 disease progression.  If death is due to an AE (e.g. cardiac disorders: cardiac arrest), report as a grade 5 event under that AE.  Participant death must also be recorded on the Death Form.  
  
11.0 MEASUREMENT OF EFFECT  
 
11.1 GI Toxicity Adverse Events  
 
Primary and Secondary Endpoints related to GI toxicity Adverse Events, as they pertain 
to the Primary and Secondary Endpoints of the study will be measured via the NIH 
National Cancer Institute (NCI ) Common Terminology Criteria for Adverse Events 
(CTCAE ) v5.0, as detailed below. 
 
11.1.1 Diarrhea Severity (Primary Endpoint)  
 
 
 
 

Version 0 3/22/2022  page 41 of 63 11.1.2 Oral Mucositis (Secondary Endpoint)  
 
 
 
 
 
11.1.3 Esophagitis  (Secondary Endpoint)  
 
 
 
 
11.1.4 Esophageal Pain (Secondary Endpoint)  
 
 
 
 
11.1.5 Gastritis (Secondary Endpoint) 
 
 
 
 
11.1.6 Abdominal Pain (Secondary Endpoint)  
 
 
 
 
11.1.7 Nausea (Secondary Endpoint)  
 
 
 
 

Version 0 3/22/2022  page 42 of 63 11.1.8 Vomiting (Secondary Endpoint)  
 
 
 
 
 
11.1.9 Enterocolitis (Secondary Endpoint)  
 
 
 
 
11.1.10  Proctitis (Secondary Endpoint)  
 
 
 
 
11.1.11  Hemorrhoids (Secondary Endpoint)  
 
 
 
 
11.2 Response Criteria  
 
Response assessment based on IMWG Response Criteria39 to be determined relative to the 
labs at time of diagnosis  prior to induction chemotherapy, as enumerated below .  
 
11.2.1 MRD negative Complete Response  
 
MRD negative complete response requires all of the following:  
 
• CR as defined below  
• Normal free light chain ratio  
• Absence of clonal cells in the bone marrow by immunohistochemistry or 
immunofluorescence  

Version 0 3/22/2022  page 43 of 63 • Absence of clonal plasma cells by NGS on bone marrow aspirate using 
ImmunoSeq B -cell receptor sequencing (Adaptive Biotechnologies)  
 
11.2.2 Stringent Complete Response  
 
Stringent complete response (sC R) requires all of the following: 
 
• CR as defined below  
• Normal free light chain ratio  
• Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence  
 
11.2.3 Complete Response  
 
Complete response (CR) requires all of the following:  
  
• Disappearance monoclonal protein by both protein electrophoresis and immunofixation studies* from the blood and urine  
• <5% plasma cells in the bone marrow  
• Disappearance of soft tissue plasmacytomas  
 
* The monoclonal protein at time of diagnosis, prior to induction 
chemotherapy, will be used for determination  
  
11.2.4 Very Good Partial Response  
 
Very good partial response (VGPR) requires all of the following:  
 
• Serum and urine monoclonal protein detectable by immunofixation* but not 
on electrophoresis  
     OR   
> 90% reduction in serum monoclonal protein with urine monoclonal 
protein < 100 mg per 24 hours  
 
* The monoclonal protein at time of diagnosis, prior to induction 
chemotherapy, will be used for determination  
 
• If present, >  50% reduction in the size of soft tissue plasmacytomas (by 
clinical or radiographic examinations) 
 
11.2.5 Partial Response  
 
Partial response (PR) requires all of the following: 
 
• > 50% reduction in the level of the serum monoclonal protein  
• Reduction in urine monoclonal protein by either >  90% or to <  200 mg  
Version 0 3/22/2022  page 44 of 63 • If present, >  50% reduction in the size of soft tissue plasmacytomas (by 
clinical or radiographic examinations) 
• If serum and urine monoclonal protein are unmeasurable, a >50% decrease 
in difference between the involved and uninvolved free light chain levels is 
required in place of monoclonal protein criteria (The absolute decrease must 
be > 10 mg/dl)  
• If serum and urine monoclonal protein are unmeasurable and serum free light chain is unmea surable, a >  50% reduction in plasma cells is required 
in place of monoclonal protein provided that baseline bone marrow plasma cell percentage was >  30%  
 
11.2.6 Minimal Response  
 
Minimal response (MR) requires all of the following: 
 
• > 25% to < 49% reduction in the level of serum monoclonal protein  
• If present, a 50 to 89% reduction in 24- hour urine monoclonal protein which 
still exceeds 200 mg/24hr  
• 25-49% reduction in the size of plasmacytomas (by clinical or radiographic 
examinations ) 
• No increase in size or number of lytic bone lesions (development of compression fracture dose not exclude response)  
 
Note:  MR includes participants in whom some but not all criteria for PR are 
fulfilled providing the remaining criteria satisfy the requirements for MR.  
  
11.2.7 Stable Disease  
 
Stable disease (SD) is defined as not meeting criteria for any other response as defined in this section.  
 
11.2.8 Progressive Disease  
 
Progressive disease (PD)  with be defined from T
0 and requires one or more of the 
following:  
  
• > 25% increase in the level of serum monoclonal protein, which must also 
be an absolute increase of at least 0.5 g/dL  
• > 25% increase in 24 -hour urine monoclonal protein, which must also be an 
absolute increase of at least 200 mg/24hr  
• > 25% increase in plasma cells in a bone marrow aspirate or on trephine 
biopsy, which must also be an absolute increase of at least 10%  
• > 25% increase in the difference between involved and uninvolved free light 
chain levels (The absolute increase must be > 10 mg/dl)  
• Definite increase in the size of existing lytic bone lesions or soft tissue 
Version 0 3/22/2022  page 45 of 63 plasmacytomas. A definite increase is defined as at least 50% (and at least 
1 cm) increase as measured serially as the sum of the products of the cross -
diameters of the lesions.  
• Development of new bone lesions or soft tissue plasmacytomas (not 
including compression fracture)  
• Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 
2.8 mmol/L not attributable to any cause other than progressive multiple 
myeloma ) 
 
Note:  A response of progressive disease nullifies any other concurrent response. 
For example, at a given time point a participant meets criteria for VGPR but has 
development of new bone lesions the response is PD not VGPR. 
  
11.2.9 Clinical Relapse  
 
Clinical relapse (i.e. progressive disease requiring alternate myeloma treatment) 
requires one or more of the following:  
 
• Decrease in hemoglobin >  2 g/dl not attributable to any cause other than 
progressive multiple myeloma  
• Increase in creatinine by > 2 mg/dl not attributa ble to any cause other than 
progressive multiple myeloma  
• Other worsening laboratory result, or clinical condition that the treating physician determines is not attributable to any cause other than progressive multiple myeloma  
 
11.2.10  Relapse from Complete Respo nse 
 
Relapse from a complete response requires a prior CR or sCR as described above and subsequently developing one or more of the following:  
 
• Reappearance of serum or urinary paraprotein on immunofixation* or 
routine electrophoresis excluding oligoclonal immune reconstitution for at least two determinations.  
• > 5% plasma cells in the bone marrow aspirate or biopsy.  
 
* The monoclonal protein at time of CR or better will be used for 
determination.  
 
11.3 Progression -Free Survival  
 
Progression- free survival (PFS) will be defined as time from D0 of auto- HCT  to 
progressive disease (biochemical and/or clinical) or death . Patients who are alive and 
progress ion-free or were lost to follow -up at the time of data analyses will be censored on 
the last known alive date. 
 
Version 0 3/22/2022  page 46 of 63 11.4 Overall Survival  
  
Overall survival (OS) will be defined as time from  D0 of auto -HCT to death due to any 
causes. Patients who are alive  or were lost to follow -up at the time of data analyses will be 
censored on the last known alive date.  
 
 
11.5 Overall Response Rate 
 
Overall response rate (ORR) will be defined as the proportion of patients meeting the criteria for PR, VGPR, CR, sCR or MRD- negative CR .   
 
11.6 Complete Response Rate 
 
Complete response rate (CRR) will be defined as the proportion of patients meeting the 
criteria CR, sCR or MRD- negative CR.  
 
 
12.0 DATA AND SAFETY MONITORING  
 
In compliance with the Washington University Institutional Data and Safety Monitoring Plan, an 
independent Data and Safety Monitoring Board (DSMB) will be specifically convened for this 
trial to review toxicity data.  A DSM B will consist of no fewer than 3 members, including 2 clinical 
investigators and a biostatistician.   DSMB members must be employed by Washington University, 
Barnes- Jewish Hospital, or St. Louis Children’s Hospital.  Like investigators, DSM B members are 
subject to the Washington Universit y School of Medicine  policies regarding standards of conduct. 
Individuals invited to serve on the DSM B will disclose any potential conflicts of interest to the 
trial principal investigator and/or appropriate university officials, in accordance with institu tion 
policies. Potential conflicts that develop during a trial or a member’s tenure on a DSM B must also 
be disclosed.  
 
The DSM report for the DSMB will be prepared by the study team with assistance from the study 
statistician, will be reviewed by the DSMB , and will be submitted to the QASM Committee.  The 
DSMB must meet at least every six months beginning six months after study activation at Washington University, no more than one month prior to the due date of the DSM report to 
QASMC.  This report will in clude:  
 
• HRPO protocol number, protocol title, Principal Investigator name, data coordinator 
name, regulatory coordinator name, and statistician. 
• Date of initial HRPO approval, date of most recent consent HRPO approval/revision, 
date of HRPO expiration, date of most recent QA audit, study status, and phase of 
study.  
• History of study including summary of substantive amendments; summary of accrual 
suspensions including start/stop dates and reason; and summary of protocol exceptions, 
error, or breach of conf identiality including start/stop dates and reason.  
• Study- wide target accrua l and study -wide actual accrual.  
Version 0 3/22/2022  page 47 of 63 • Protocol activation date.  
• Average rate of accrual observed in year 1, year 2, and subsequent years.  
• Expected  accrual end date , and accrual by group.  
• Objectives of protocol with supporting data and list the number of participants who 
have met each objective.  
• Measures of efficacy.  
• Early stopping rules with supporting data and list the number of participants who have met the early stopping rules . 
• Summary  of toxici ties. 
• Abstract submissions/publications . 
• Summary of any recent literature that may affect the safety or ethics  of the study.  
 Further DSMB responsibilities are described in the DSMB charter.  
 The study principal investigator and c oordinator will monitor for serious toxicities on an ongoing 
basis. Once the principal investigator or c oordinator becomes aware of an adverse event, the AE 
will be reported to the HRPO and QASMC according to institutional guidelines  (please refer to 
Section 7.0) . 
 Refer to the Washington University Quality Assurance and Data Safety Monitoring Committee 
Policies and Procedures for full details on the responsibilities of the DSMB. This is located on the QASMC website at https://siteman.wustl.edu/research/clinical -research -resources/protocol -
office -prmcqasmc/.   
  
13.0 STATISTICAL CONSIDERATIONS  
 
13.1 Statistical Hypotheses  
 
Prophylactic administration of uproleselan (GMI- 1271) throughout melphalan 
conditioning in preparation for auto- HCT will reduce the rate of diarrhea, as assessed by a 
validated chemotherapy- related diarrhea severity scoring system (CTCAE v5.0 Diarrhea).  
 
13.2 Sample Size Determination  
 
We expect an event rate of diarrhea of any grade of 90% with a distribution of Grade 1: 
20%, Grade 2: 30%, Grade 3: 40%, Grade 4: 0% and Grade 5: 0%. We estimate a sample 
size of 50 patients (25 per arm) evaluable for the primary endpoint would provide 80% power (alpha 0.20) to detect a n odds ratio (OR) of 0.42 for  reduction in the grade of 
diarrhea severity, using a one -sided proportional  odds model for ordinal categorical data.  
We anticipate that more power could be achieved in the actual analysis because of richer information (daily during hospitalization) available for GI toxicity evaluation. Note that one purpose of a randomized phase  II trial design is to detect signals of efficacy in an 
experimental regimen for further evaluation rather than to have a definitive conclusion regarding the efficacy of an experimental regimen. Therefore, a relatively larger type I error (alpha or false p ositive error) is acceptable in a randomized phase II setting and the 
Version 0 3/22/2022  page 48 of 63 level of type I error can be relaxed to alpha=0.2,  according to Korn et al40 and Rubinstein 
et al41.   
 
13.3 Population for Analyses  
 
All randomized patients evaluable for the primary and sec ondary endpoints will be 
analyzed on an intention- to-treat basis. Additionally, the same patient population will also 
be analyzed on a per -protocol basis for the same endpoints.  
 
13.4 Statistical Analyses  
 
13.4.1 General Approach  
 
In general, categorical variables wi ll be expressed as percentages of the total 
number of patients meeting that endpoint. Continuous data will typically be 
expressed as a median value.   
 
13.4.2 Analysis of the Primary Endpoint  
 
The primary endpoint will be the change in diarrhea severity (CTCAE v5.0, Figure 
2) in patients receiving high- dose melphalan conditioning in preparation for auto-
HCT for MM who receive prophylactic uproleselan (GMI -1271) plus standard of 
care (SOC) compared to placebo plus SOC. All randomized pati ents meeting 
eligibility criteria who receive at least one dose of uproleselan or placebo and who 
undergo a melphalan- conditioned auto- HCT will be evaluable for the primary 
endpoint analysis based on an intent -to-treat principle. Patients will also be 
evaluated for the primary endpoint based on a per -protocol analysis. The outcome 
will be reported  as a median score with high/low ranges for the duration of the 
hospitalization, comparing the treatment and placebo cohorts .  The primary 
endpoint is anticipated to follow a non- normal distribution and the overall 
difference between arms will be compared using generalized estimation equation (GEE) which is less sensitive to parametric distributions.  
 
Figure 2: CTCAE v5.0 Diarrhea Score : 
 
 
 
13.4.3 Analysis of the Seconda ry Endpoint s 
 
All secondary endpoints will be analyzed using the appropriate, descriptive 
statistics on an intent -to-treat and per -protocol basis , comparing the treatment and 

Version 0 3/22/2022  page 49 of 63 placebo cohorts . However, the study will not be powered to detect significant 
differences in these outcomes.   
 
• Change in mucositis severity  (per CTCAE v5.0 Oral Mucositis criteria) and 
change in alternative GI toxicities (e.g. esophagitis, enterocolitis, etc. ; per 
CTCAE v5.0)  will be reported as median scores with high/low ranges for 
the duration of the hospitalization.  
 
• Time  to neutrophil engraftment defined as ANC ≥0.5 x 109/L for 3 
consecutive days or ≥1.0 x 109/L for 1 day will be reported as a median time 
engraftment . 
 
• Duration of hospital LOS  will be reported in median number of days , from 
date of admission for auto- HCT to date of discharge . 
 
• Quantitative use of anti -diarrheal medications will be reported as the 
median number of daily doses administered (loperamide, diphenoxylate, 
etc.) and pain medications will be reported as the median number of daily  
morphine equivalents , minus the baseline level of morphine equivalents the 
patient may have been taking prior to admission as an outpatient 
medication . 
 
• Nutritional status before conditioning and at D+14 or date of discharge 
(whichever is sooner), will be reported as the median number of TPN days  
and in change in standing weight comparing D -3, D+8 and date of discharge 
or D+14 (whichever is sooner) . 
• Change in Bristol Stool Scale, assessed daily  (see Appendix D) , will be 
reported as the median stool type  with high/low ranges . 
 
• Incidence of infection will be reported as a percentage of patients who develop of bacteremia during the hospitalization for HCT  (with organism 
reported when available), median time to first antibiotics and percentage of 
patients who develop a c. diff infection . 
 
• The differences between treatment arms will be described using GEE (for 
longitudinal endpoints such as mucositis severit y, Bristol Stool Scale, 
nutritional status, etc.), Kaplan -Meier product limit methods and log- rank 
test (for time -to-event endpoints such as time to neutrophil engraftment, 
length of hospital stay, etc.), and Fisher’s exact test (for incidence of 
infection ) as appropriate.  
 
13.4.4 Analysis of the Exploratory Endpoints  
 
Correlative Endpoints:  
• Minimal Residual Disease (MRD) testing via ImmunoSeq B -cell receptor 
sequencing (Adaptive Biotechnologies)  at D+100 , expressed as percentage 
Version 0 3/22/2022  page 50 of 63 of patients being MRD negative, comparing the treatment and placebo 
cohorts . 
 
• Soluble E -selectin levels by ELISA assay at pre- dose (D -3) and post -
conditioning (D -0) time points , comparing the treatment and placebo 
cohorts . 
 
• Fecal  calprotectin , lipocalin -2 and any additional fecal biomarkers on D -3, 
D0, D+8 and date of discharge or D+14 (whichever is sooner) , comparing 
the treatment and placebo cohorts  
 
• Progression Free Survival (PFS) with up to 2 -year follow up assessed by 
time-to event (Kaplan -Meier analysis) , comparing the treatment and 
placebo cohorts  
 
• Overall Survival (OS) with up to 2- year follow up assessed by time- to event 
(Kaplan -Meier analysis) , comparing the treatment and placebo cohorts  
 
• The differences between treatment arms will be described using Wilcoxon -
Mann -Whitney or GEE (soluble E -selectin levels,  fecal biomarkers,  etc.), 
Kaplan -Meier product limit methods and log- rank test (PFS, OS), and 
Fisher’s exact test (minimal residual disease at Day 100) , as appropriate.  
 
13.4.5 Analysis of the PRO/QoL Endpoint 
 
PRO and QoL scores assessed via the CTCAE PRO Form v1.0 with items selected 
for relevance to GI toxicity and patient quality of life (see Supplement 1) will be 
reported as median scores on D -3, D+ 8 and date of discharge or D+14 (whichever 
is sooner) , comparing the tre atment and placebo cohorts.  
 
13.4.6 Baseline Descriptive Statistics  
 
Baseline characteristics, including demographics, laboratory measurements, 
induction treatment regimens and disease response status at the time of HCT will be reported, using descriptive statistics.  
 
13.4.7 Safety Analyses  
 
An independent data monitor will assess for treatment- related death and/or  non-
engraftment , with e nrollment suspended for review whenever there is any case of  
treatment- related death or non -engraftment.   
 Non-engraftment  will be defined as failure to achieve neutrophil engraftment (ANC 
≥0.5 x 10
9/L for 3 consecutive days or ≥1.0 x 109/L for 1 day) by post -HCT D+21. 
Additionally, all patients participating in the study must have mobilized sufficient CD34+ HSCs for initial auto -HCT and a mandatory back- up graft (total cells 
Version 0 3/22/2022  page 51 of 63 collected: ≥5.0 x 106 CD34+ cells/kg; and cells per HCT: ≥2.5 x 106 CD34+ 
cells/kg).  
 
A Bayesian safety monitoring rule will also be implemented for each arm separately 
once the first 5 evaluable subjects  are available in the given arm. The stopping rule  
is defined as Pr(θ T > 0.2 |data)>0.7, where θ T denotes the incidence of Grade 3 or 
higher  non- hematologic , uproleselan- related toxicities , with the exception of 
toxicities reported in >25% of patients rece iving high- dose melphalan conditioning, 
as detailed  in Section 1.3.2. T hat is, enrollment will be stopped early whenever, 
given the accumulated observed data, there is a high probability (>70%) that the incidence of targeted toxicities  is above 20%. The st opping boundaries are obtained 
using the online study design tools from M.D. Anderson Cancer Center 
(https://www.trialdesign.org/one -page -shell.html#BTOX). Specifically, we 
assume that θ
T follows a beta distribution, beta (α + x, β + n – x), where x and n- x 
represent the observed numbers of toxicity and non- toxicity  cases, while α and β 
are parameters for prior distribution. We set the prior as beta (0.5, 0.5), i.e., with a 
non-informative  prior. A  treatment arm  will be recommended to stop for excessive 
toxicities if we observe 2 events  out of the first 5 subjects, 3 events out of 10 
subjects, 4 events  out of 15 subjects,  5 events  out of 20 subjects,  or 6th event  
observed before the last subject enrolled.  A simulation study (with 1000 simulated 
trials) is also performed to assess the operating characteristics of the above 
monitoring rule. With a true toxicity rate of 10%, there will be only 14% chance of 
early termination. Conversely, there  will be 88% chance of claiming excessive 
toxicity when the true toxicity rate is 30%.  
13.4.8 Interim Analyses for Futility  
 
An interim analysis will be scheduled t o protect patients from receiving inferior 
treatment.  An interim analysis will be performed after the first 50% patients are 
randomized. The summary statistics for primary endpoint ( diarrhea severity  during 
hospital stay) will be calculated. An early termination due to futility will be 
recommended if the statistics of the primary endpoint are in favor of the control 
arm
42. 
 
 
  
Version 0 3/22/2022  page 52 of 63 14.0 REFERENCES  
 
1. Rajkumar SV. Multiple myeloma. Curr Probl Cancer . 2009;33(1):7 -64. 
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet Lond Engl . 2009;374(9686):324- 339. 
3. Ludwig H, Beksac M, Bladé  J, et al. Current multiple myeloma treatment strategies with novel 
agents: a European perspective. The Oncologist . 2010;15(1):6- 25. 
4. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myelom a. Mayo Clin Proc . 2003;78(1):21- 33. 
5. Lin P. Plasma cell myeloma. Hematol Oncol Clin North Am . 2009;23(4):709- 727. 
6. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med . 
1996;335(2):91–97. 
7. Child JA, Morgan GJ, Davies FE, et al. High- dose chemotherapy with hematopoietic stem - 
cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–1883. 
8. Fermand J -P, Katsahian S, Divine M, et al. High -dose therapy and autologous blood stem - cell 
transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long -term results of a randomized control trial from the Group Myelome - Autogreffe. J 
Clin Oncol Off J Am Soc Clin Oncol . 2005;23(36):9227- 9233. 
9. Brenner H, Gondos A, Pulte D. Recent major improvement in long- term survival of younger 
patients with multiple myeloma. Blood. 2008;111(5):2521 -2526. 
10. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma  and 
the impact of novel therapies. Blood. 2008;111(5):2516- 2520.  
11. Ludwig H, Durie BGM, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients 
from the  International Myeloma Working Group. Blood. 2008;111(8):4039- 4047. 
12. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046- 1060.  
13. Mccarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide Maintenance After Autologous Stem -Cell Transplanta tion in Newly Diagnosed Multiple Myeloma: A Meta -Analysis. J Clin 
Oncol. 2017;35(29):3279- 3289. 
14. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Mye  ́lome 9502 randomized trial. Blood. 2002; 99(3):731-735. 
15. Hari P, Aljitawi OS, Arce -Lara C, et al. A Phase IIb, Mult icenter, Open- Label, Safety, and 
Efficacy Study of High- Dose, Propylene Glycol -Free Melphalan Hydrochloride for Injection 
(EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. Biol Blood Marrow Transpl ant. 2015;21:2100- 2105. 
16. Gyurkocza B and Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344- 353. 
17. Malek E, Creger R, Kolk M, et al. Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti -Myeloma 
Effect. Blood. 2017;130(1):680.  
18. Toro JJ, Arango JI, Westbrook SD, et al. Oral Mucositis Measured by the Oral Mucositis Assessment Scale (OMAS), but Not by the World Healt h Organization (WHO) Scoring 
Version 0 3/22/2022  page 53 of 63 System, Correlates with Nutritional Changes after Autologous Peripheral Blood Stem Cell 
Transplantation. Blood. 2007;110(11):4944.  
19. Schuster MW, Shore TB, Greenburg J, et al. Phase I Trial of CG53135- 05 to Prevent Mucositis 
in Patients Undergoing High- Dose Chemotherapy (HDCT) and Autologous Peripheral Blood 
Stem Cell Transplantation (PBSCT). Blood. 2004;104(11):1161. 
20. Malek E, Gupta V, Creger R, et al. Amifostine reduces gastro -intestinal toxicity after 
autologous transplantation for multiple myeloma. Leukemia & Lymphom a. 2018;59(8):1905 -
1912. 
21. Dans M, Kutner JS, Baker JN, et al. NCCN Clinical Practice Guidelines in Oncology: 
Palliative Care. Version 2.2019. 
https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf. 
22. Ley K, Tedder  TF. Leukocyte  interactions  with vascular  endothelium. New insights  into 
selectin -mediated  attachment  and rolling.  J Immunol. 1995;155(2):525 -528. 
23. Winkler IG, Barbier V, Nutt HL, et al. Administration Of E -Selectin Antagonist GMI - 1271 
Improves Survival After High -Dose Chemotherapy By Alleviating Mucositis and Accelerating 
Neutrophil Recovery. Blood. 2013;122(21):2266 -2266.  
24. Bertani L, Mumolo MG, Tapete G, et al. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol. 2020;32(9):1091 -1098. 
25. Malik MN, Rafae A, Durer C, Durer S, Anwer F. Fecal Calprotectin as a Diagnostic and Prognostic B iomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review 
of Literature. Cureus. 2019;11(2):e4143. 
26. Weber D, Weber M, Hippe K, et al. Non- invasive diagnosis of acute intestinal graft -versus -
host disease by a new scoring system using ultra sound morphology, compound elastography, 
and contrast -enhanced ultrasound. Bone Marrow Transplant. 2019;54(7):1038- 1048. 
27. Moschen AR, Adolph TE, Gerner RR, Wieser V, Tilg H. Lipocalin -2: A Master Mediator of 
Intestinal and Metabolic Inflammation. Trends End ocrinol Metab. 2017;28(5):388 -397. 
28. Hermann A, Winkler A, Paschen C, et al. Lipocalin- 2 levels in acute and chronic graft -versus -
host disease following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2019;74:25- 32.e1. 
29. Husain N, Tokoro K, Popov JM, Naides SJ, Kwasny MJ, Buchman AL. Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis. J Clin Gastroenterol. 2013;47(3):246- 51. 
30. Nancey S, Boschetti G, Moussata D, et al. Neopterin is a novel reliable fe cal marker as accurate 
as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2013;19(5):1043 -52. 
31. Winkler IG, Barbier V, Ward M, et al. Vascular E -Selectin Protects Leukemia Cells from 
Chemotherapy by Directly Activating Pro- Survival NF -Kb Signalling -  Therapeutic Blockade 
of E-Selectin Dampens NF -Kb Activation. Blood. 2016;128(22):2823- 2823. 
32. Winkler IG, Erbani JM, Barbier V, et al. Vascular E -Selectin Mediates Chemo - Resistance in 
Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL -1 (CD162) and Hcell 
(CD44) and AKT Signaling. Blood. 2017;130(Suppl 1):793 -793.  
33. Winkler IG, Barbier V, Nowlan B, et al. Vascular niche E -selectin regulates hematopoietic 
stem cell dormancy, sel f- renewal and chemoresistance. Nat Med. 2012;18(11):1651 -1657. 
34. GlycoMimetics, Inc. Uproleselan (GMI -1271) Investigator’s Brochure. Edition No. 6, 4/2018. 
35. Muz B, Azab F, Fiala M, et al. Inhibition of E -Selectin (GMI -1271) or E -selectin together with 
CXCR4 (GMI -1359) re -sensitizes multiple myeloma to therapy. Blood Cancer J. 2019;9(9):68. 
Version 0 3/22/2022  page 54 of 63 36. Hahn TE, Wallace PK, Fraser R, et al. Minimal residual disease (MRD) assessment before and 
after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for  multiple 
myeloma: Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) study. 2019 TCT  Meetings. Abstract 6. Presented February 22, 2019. 
37. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and m aintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial. J Clin 
Oncol . 2019;37:589- 597. 
38. Natoni A, Smith TAG, Keane N, et al. E -selectin ligands recognized by HECA452 induce drug 
resistance in myeloma, which is overcome by the E -selectin a ntagonist, GMI -1271. Leukemia. 
2017;31(12):2642- 2651.  
39. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328- e346. 
40. Korn EL, Freidlin B. Interim monitoring for non- inferiority trials: minimizing patient exposure 
to inferior therapies. Ann Oncol. 2018;29(3):573- 577. 
41. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP. Design issues of randomized phase II trials and  a proposal for phase II screening trials. J Clin Oncol 2005;23:7199–7206. 
42. Wieand S, Schroeder G, O'Fallon JR. Stopping when the experimental regimen does not appear to help. Stat Med 1994;13:1453- 1458. 
 
  
Version 0 3/22/2022  page 55 of 63  
APPENDIX A: ECOG Performance Status Scale  
 
 
Grade  
  
Description  
0 Normal activity.  Fully active, able to carry on all pre -disease 
performance without restriction.  
1 Symptoms, but ambulatory.  Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work).  
2 In bed <50% of the time.  Ambulatory and capable of all self -care, but 
unable to carry out any work activities.  Up and about more than 50% of waking hours.  
3  
In bed >50% of the time.  Capable of only limited self -care, confined 
to bed or chair more than 50% of waking hours.  
 
4 100% bedridden.  Completely disabled.  Cannot carry on any self -care.  
Totally confined to bed or chair.  
5  
Dead.  
 
   
Version 0 3/22/2022  page 56 of 63 APPENDIX B: Definitions for Adverse  Event Reporting  
 
A. Adverse Events (AEs)  
 
As defined in 21 CFR 312.32:  
 
Definition: any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug- related.  
 
Grading:  the descriptions and grading scales found in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.  A copy of the CTCAE version 5.0 can be downloaded from the CTEP website.  
 Attribution (relatedness), Expectedness, and Seriousness:  the definitions for the terms 
listed that should be used are those provided by the Department of Health and Human Services’ Office for Human Research Protections (OHRP).  A copy of this guidance can be found on OHRP’s website:  
http://www.hhs.gov/ohrp/policy/advevntguid.html
 
 
B. Suspected Adverse Reaction (SAR)  
 
As defined in 21 CFR 312.32:  
 
Definition: any adverse event for which there is a reasonable possibility that the drug caused 
the adverse event.  “Reasonable possibility” means there is evidence to suggest a causal 
relationship between the drug and the adverse event.  “Suspected adverse reaction” implies a 
lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug. 
 
C. Life-Threatening Adverse Event / Life Threatening Suspected Adverse Reaction  
 
As defined in 21 CFR 312.32:  
 
Definition:  any adverse drug event or suspected adverse reaction is considered “life-
threatening” if, in the view of the investigator, its occurrence places the patient at immediate risk of death. It does not include an adverse event or suspected adverse reaction that, had it 
occurred in a more severe form, might have caused death.  
 D.  Serious Adverse Event (SAE ) or Serious Suspected Adverse Reaction  
 
As defined in 21 CFR 312.32:  
 
Definition:  an adverse event or suspected adverse reaction is considered “serious” if, in the 
view of the investigator, it results in any of the following outcomes:  
o Death  
o A life -threatening adverse event  
Version 0 3/22/2022  page 57 of 63 o Inpatient hospitalization or prolongation of existing hospitalization  
o A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions  
o A congenital anomaly/birth defect  
o Any othe r important medical event that does not fit the criteria above but, based upon 
appropriate medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above  
 
E. Protocol Exceptions  
 
Defin ition: A planned change in the conduct of the research for one participant.  
 
F. Deviation  
 
Definition: Any alteration or modification to the IRB -approved research without prospective 
IRB approval.  The term “research” encompasses all IRB -approved materials and documents 
including the detailed protocol, IRB application, consent form, recruitment materials, 
questionnaires/data collection forms, and any other information relating to the research study.  
 A minor or administrative deviation is one that does not have the potential to negatively impact the rights, safety, or welfare of participants or others or the scientific validity of the study.  
 A major deviation is one that does have the potential to negatively impact the rights, safety, or welfare of participant s or others or the scientific validity of the study.  
Version 0 3/22/2022  page 58 of 63 APPENDIX C: Reporting Timelines  
 
Expedited Reporting Timelines  
Event  HRPO  QASMC  FDA  Glycomimetics, Inc. 
Serious AND 
unexpected suspected 
adverse reaction    Report no later than 15 calendar 
days after it is determined that 
the information qualifies for 
reporting  Completed Regulatory Form 
(MedWatch / CIOMS I) for 
initial and follow -up in parallel 
with submission to the FDA for 
patients exposed to GMI 
product.  
Unexpected fatal or 
life-threatening 
suspected adverse 
reaction    Report no later than 7 calendar 
days after initial receipt of the information  Completed Regulatory Form 
(MedWatch / CIOMS I) for initial and follow -up in parallel 
with submission to the FDA for patients exposed to GMI 
product.  
Unanticipated 
problem involving risk 
to participants or 
others  Report within 10 working days.  If the event 
results in the death of a participant enrolled at 
WU/BJH/SLCH, report within 1 working day.  Report via email 
after IRB ackno wledgment   In parallel with the submission 
to the HRPO.  
Major deviation  Report within 10 working days.  If the event 
results in the death of a participant enrolled at 
WU/BJH/SLCH, r eport within 1 working day.     
A series of minor 
deviations  that are 
being reported as a 
continuing 
noncompliance  Report within 10 working days.      
Protocol exception  Approval must be obtained prior to 
implementing the change     
Clinically important 
increase in the rate of 
a serious suspected 
adverse reaction of 
that list in the protocol 
or IB    Report no later than 15 calendar 
days after it is determined that 
the information qualifies for 
reporting  In parallel with submission to 
the FDA.  
Version 0 3/22/2022  page 59 of 63 Expedited Reporting Timelines  
Event  HRPO  QASMC  FDA  Glycomimetics, Inc. 
Complaints  If the complaint reveals an unanticipated 
problem involving risks t o participants or others 
OR noncompliance, report within 10 working 
days.  If the event results in the death of a participant enrolled at WU/BJH/SLCH, report 
within 1 working day.  Otherwis e, report at the 
time of continuing review.     
Breach of 
confidentiality  Within 10 working days.     
Incarceration  If withdrawing the participant poses a safety 
issue, report within 10 working days.   
 
If withdrawing the participant does not represent a safety issue and the patient will be 
withdrawn, report at continuing review.     
 
Routine Reporting Timelines  
Event  HRPO  QASMC  FDA  Glycomimetics, Inc.  
Adverse event  or SAE 
that does not require 
expedited reporting  If they do not meet the definition of an  
unanticipated problem involving risks to 
participants or others, report summary 
information at the time of continuing review  Adverse events will be 
reported in the toxicity 
table in the DSM report 
which is typically due 
every 6 months.  The most current 
toxicity table from the 
DSM report is provided to the FDA with the 
IND’s annual report.  All SAEs and follow -up 15 
days post -Sponsor awareness 
date for patients exposed to GMI product.  
Overdose, pregnancy, 
and lactation cases not 
associated with an 
SAE where a subject 
was exposed to 
GlycoMimetics 
compound     Completed Regulatory Form 
(MedWatch / CIOMS I) for 
initial and follow -up in parallel 
on a monthly cycle.  
Minor deviation  Report summary information at the time of 
continuing review.     
Complaints  If the  complaint reveals an unanticipated problem 
involving risks t o participants or others OR    
Version 0 3/22/2022  page 60 of 63 noncompliance, report within 10 working days.  If 
the event results in the death of a participant 
enrolled at WU/BJH/SLCH, report within 1 
working day.  Otherwise, rep ort at the time of 
continuing review.  
Incarceration  If withdrawing the participant poses a safety 
issue, report within 10 working days.   
 
If withdrawing the participant does not represent a safety issue and the patient will be withdrawn, 
report at continuing review.     
Version 0 3/22/2022  page 61 of 63 APPENDIX D: Bristol Stool Scale  
 
 
 
  

Version 0 3/22/2022  page 62 of 63 SUPPLEMENT 1: GI -Specific NCI CTCAE PRO v1.0 
As individuals go through treatment for their cancer they sometimes experience different 
symptoms and side effects. For each question, please check or mark an  in the one box that 
best describes your experiences over the past 7 days...  
 
1.  In the last 7 days, what was the SEVERITY of your DIFFICULTY SWALLOWING at its WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
2.  In the last 7 days, what was the SEVERITY of your MOUTH OR THROAT SORES at their WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
In the last 7 days, how much did MOUTH OR THROAT SORES INTERFERE with your usual or 
daily activities?  
○ Not at all  ○ A little bit  ○ Somewhat  ○ Quite a bit  ○ Very much  
3.  In the last 7 days, what was the SEVERITY of your DECREASED APPETITE at its WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
In the last 7 days, how much did DECREASED APPETITE INTERFERE with your usual or daily 
activities?  
○ Not at all  ○ A little bit  ○ Somewhat  ○ Quite a bit  ○ Very much  
4.  In the last 7 days, how OFTEN did you have NAUSEA?  
○ Never  ○ Rarely  ○ Occasionally  ○ Frequently  ○ Almost constantly  
In the last 7 days, what was the SEVERITY of your NAUSEA at its WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
5.  In the last 7 days, how OFTEN did you have VOMITING?  
○ Never  ○ Rarely  ○ Occasionally  ○ Frequently  ○ Almost constantly  
In the last 7 days, what was the SEVERITY of your VOMITING at its WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
6.  In the last 7 days, how OFTEN did you have HEARTBURN?  
○ Never  ○ Rarely  ○ Occasionally  ○ Frequently  ○ Almost constantly  
In the last 7 days, what was the SEVERITY of your HEARTBURN at its WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
7.  In the last 7 days, did you have any INCREASED PASSING OF GAS (FLATULENCE)?  
○ Yes  ○ No  
8.  In the last 7 days, how OFTEN did you have BLOATING OF THE ABDOMEN (BELLY)?  
○ Never  ○ Rarely  ○ Occasionally  ○ Frequently  ○ Almost constantly  
In the last 7 days, what was the SEVERITY of your BLOATING OF THE ABDOMEN (BELLY) at its 
WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
9.  In the last 7 days, how OFTEN did you have LOOSE OR WATERY STOOLS (DIARRHE A)?  
○ Never  ○ Rarely  ○ Occasionally  ○ Frequently  ○ Almost constantly  
10.  In the last 7 days, how OFTEN did you have PAIN IN THE ABDOMEN (BELLY AREA)?  
○ Never  ○ Rarely  ○ Occasionally  ○ Frequently  ○ Almost constantly  

Version 0 3/22/2022  page 63 of 63 In the last 7 days, what was the SEVERITY of your PAIN IN THE ABDOMEN (BELLY AREA) at its 
WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
In the last 7 days, how much did PAIN IN THE ABDOMEN (BELLY AREA) INTERFERE with your 
usual or daily activities?  
○ Not at all  ○ A little bit  ○ Somewhat  ○ Quite a bit  ○ Very much  
 
11.  In the last 7 days, how OFTEN did you LOSE CONTROL OF BOWEL MOVEMENTS?  
○ Never  ○ Rarely  ○ Occasionally  ○ Frequently  ○ Almost constantly  
In the last 7 days, how much did LOSS OF CONTROL OF BOWEL MOVEMENTS INTERFERE with 
your usual or daily activities?  
○ Not at all  ○ A little bit  ○ Somewhat  ○ Quite a bit  ○ Very much  
Do you have any other symptoms that you wish to report?  
○ Yes  ○ No  
Please list any other symptoms:  
1.  In the last 7 days, what was the SEVERITY of this symptom at its WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
2.  In the last 7 days, what was the SEVERITY of this symptom at its WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
3.  In the last 7 days, what was the SEVERITY of this symptom at its WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
4.  In the last 7 days, what was the SEVERITY of this symptom at its WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
5.  In the last 7 days, what was the SEVERITY of this symptom at its WORST?  
○ None  ○ Mild  ○ Moderate  ○ Severe  ○ Very severe  
 